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Abstract 
The characteristics of an EP3 constrictor system were investigated on the isolated rat 
femoral artery (RFA). Ring preparations of the femoral artery from Sprague-Dawley 
rats were bathed in Krebs-Henseleit solution containing indomethacin (1 |j.M) and 
the TP receptor antagonist GR-32191 (1 j^M). L-NAME (100 ^iM) was added to 
remove NO-mediated relaxation. Isometric tension changes were measured in a 
small vessel myograph. 
Marked synergism was observed between the EP3 receptor agonists, sulprostone，SC-
46275 and 17-phenyhPGE2 and other contractile agents (phenylephrine, K ^ on the 
artery preparation. Acting alone, each EP3 agonist produced a weak contractile effect 
that was less than one sixth of the maximum response of the TP agonist U-46619. 一 
The phenylephrine (100nM)/sulprostone combination induced contraction equivalent 
to 4 times the sum of their responses when acting alone, with EC50 value of 0.92 nM. 
Similar synergism was seen with KCl ( 1 0 - 3 0 mM) pre-contraction. The synergism 
was found to be mutual; KCl response on the RFA was also enhanced by pre-
contraction with a threshold dose of sulprostone. 
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The ranking of agonist potency for the synergism, SC-46275 = sulprostone > 17-
phenylephrine » fluprostenol (selective FP agonist) indicates the involvement of 
EP3 as opposed to EPi or FP receptors. Experiments with the EPi receptor antagonist 
SC-51322 confirmed this. 
The roles of L-type Ca^^ channels and Rho-kinase in the synergism were investigated. 
Contractions induced by KCl, phenylephrine and U-46619 were similarly inhibited 
by nifedipine (IC50 = 4，4.7 and 5.5 nM respectively). Nifedipine (100 nM) caused 
more than 90% reversal of synergistic contractions produced by the 
phenylephrine/sulprostone and sulprostone/KCl combinations. The specific Rho-
kinase inhibitors Y-27632 and H-1152 were also found to inhibit the contractions 
produced by phenylephrine/sulprostone combination with IC50 values of 0.23 and 0.6 
)J.M respectively. 
On the other hand, sulprostone was found to produce a vasodilator effect in vivo. 
Using a laser Doppler perfusion imaging technique, it was demonstrated that 
sulprostone (ICT� and 10'^  mol) increased the blood flow of rat knee joint. Further 
investigation is required to elucidate the underlying mechanism. 
_ In conclusion, contractions induced by the EP3 receptor agonists on the RPA were 
enhanced by the presence of other vasoactive agents. The importance of L-type 
calcium channel opening for contraction is apparent. From the experiments with 
Rho-kinase inhibitors, Rho-kinase activation also appears to be a major mechanism 






(1 i^M)，TP 受體拮抗劑 GR-32191 (1 i^M)的 Krebs-Henseleit 溶液亵。實驗 
中，在Krebs-Henseleit溶液裹加入L-NAME目的是消除NO-介導的血管舒 





也能產生出相似的效果。但是，用苯腎上腺素（phenylephrine; 30-300 n M )預 
收缩動脈環能夠增強EP3受體激動劑引發的收缩效應。苯腎上腺素（100 n M ) 
/sulprostone聯合引發的收缩效應是它們單獨效應的總和之四倍，ECso值為0.92 
nMo 








90%以上。 特異的R h o -激酸抑制劑Y - 2 7 6 3 2和H - 1 1 5 2可抑制由 
phenylephrine/sulprostone合用產生的收缩效應，IC50值分別為0.23和0.6 |JV[� 
另外，sulprostone在體內(in vivo)可產生血管擴張作用。利用激光 
Doppler灌注影像技術証實sulprostone (lO'^®和10'9 mol)可增加大鼠膝關節的血 
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Chapter 1 - Introduction 
Chapter 1 Introduction 
Prostaglandin E2 (PGE2) is a product of the cyclooxygenase pathway from 
arachidonic acid. PGE2 exerts a variety of actions in the vasculature due to its 
interactions with different EP receptor subtypes. There are four EP receptor subtypes 
designated as EPi, EP2, EP3 and EP4. Each of these subtypes demonstrates distinct 
ligand selectivity and signal transduction profiles. The EP receptor subtypes can be 
grouped into two categories according to their biological effects on smooth muscle. 
EP2 and EP4 are the relaxant receptors whereas EP! and EP3 are the contractile 
receptors. 
The contractile EP3 receptor in vascular preparations is the focus of this study. The 
_ EP3 receptor-mediated vasoconstriction was investigated in isolated rat femoral 
artery using a small vessel myograph. The in vivo effect of sulprostone, an EP3 
receptor agonist was then tested using the laser Doppler perfusion imaging technique. 
Before the description and discussion of the experiments, the characteristics of the 
-contract i le prostanoid receptors are briefly reviewed and a few aspects of the role of 
calcium in vasoconstriction are discussed in the Introduction section. 
1.1 Prostanoids and vasoconstriction 
With the advent in cloning and sequencing of the prostanoid receptors, studies in 
molecular evolution with computer-assisted sequence comparison revealed that EP3, 
EPi, FP and TP receptors are belonged to the same cluster in the phylogenetic tree 
(Toh et al, 1995). Indeed, these four prostanoid receptors share some functional and 
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signal transduction properties apart from sequence homology. The ligand binding 
properties, selectivity of agonists and antagonists, signal transduction, characteristics 
of multiple isoforms and receptor distribution of these contractile prostanoid 
receptors are discussed below. 
1.1.1 EP3 receptors 
1.1.1.1 Ligand binding properties 
Radioligand binding allows direct analysis of drug-receptor interaction without 
taking into account the functional outcome of the interaction. With the advance of 
expressing recombinant prostanoid receptors in different cell lines, scientists have 
been able to assess the affinity and selectivity of a range of agonists and antagonists 
at the individual prostanoid receptors at high expression levels. EP3 receptors have 
been cloned from several species including mouse, rat, man, rabbit and cow. 
PGE2 binds to recombinant—EP3 receptors from man (Abramovitz et al., 2000), rat 
(Boie et al” 1997) and mouse (Kiriyama et al., 1997) with the highest affinity among 
the EP receptor subtypes, with Kd values of 0.33，0.83 and 1.4 nM respectively. 
Table 1.1 shows the K\ values of PGE2 and its analogues for the human, rat and 
mouse EP3 receptors. The ranking of affinity for the human EP3 receptor was M&B-
28767 = PGE2 = sulprostone > GR-63799 = misoprostol free acid = enprostil > 
misoprostol methyl ester (Abramovitz et al., 2000). Boie and co-workers reported 
the rank order of affinity for the rat EP3 receptor was M&B-28767 = sulprostone = 
PGE2 = PGEi = 11-deoxy-PGEi = 17-phenyl-PGE2 > GR-63799 = enprostil > 
misoprostol (Boie et al., 1997). For the mouse EP3 receptor, the ranking of affinity 
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was sulprostone = M&B-28767 = PGE2 = PGE! = 11-deoxy-PGEi = GR-63799 = 
16,16-dimethyl-PGE2 = 17-phenyl-PGE2 > misoprostol (Kiriyama et al., 1997). 
Table 1.1 Competition for radioligand binding to recombinant EP3 receptors 
Species (receptor) Human (EP3-111) Rat (EPsa) Mouse (EPsa) 
Cell line HEK 293(EBNA) HEK 2 9 3 ( E B N A ) C H O 
Reference (Abramovitz et al., (Boie et al, 1997) (Kiriyama et al” 
2000) 1997) 
Ligands K\ values (nM) 
P G E 2 0 3 3 | ~ 0 9 0 . 8 5 
P G E I N T U U 
11-deoxy-PGEi OT 32 L5 
Sulprostone ^ ^ 
M&B28767 014 03 
GR63799 ^ T^ 
17-PHENYI-PGE2 N T 4 3 3 J 
Enprostil 12 " 14 NT 
Misoprostol FA T9 ^ ~ 
~ M E 3 \ 9 
NT: not tested; FA: free acid; ME: methyl ester; [•^ H]PGE2 was the radioligand. 
All the compounds show cross-reactivity with at least one other prostanoid receptor. 
Sulprostone appeared to be the most selective agonist at the EP3 receptor although it 
also bound to the human EPi and FP receptors, with K�values of 107 and 198 nM 
respectively (Abramovitz et al., 2000). In rat EPi-expressing HEK 293 cells, 
3 
Chapter 1 - Introduction 
sulprostone was reported to be a partial agonist (Boie et al., 1997). Further evidence, 
for example its interaction with PGE2，is required to confirm this phenomenon. 
M&B-28767 is also a potent EP3 receptor agonist but it binds to the human 
(Abramovitz et al” 2000)，rat (Boie et al., 1997) and mouse (Kiriyama et al, 1997) 
EP4 receptors with K\ of 10，24 and 500 nM respectively. It also binds to human TP 
receptor with greater affinity {Kt = 343 nM) than sulprostone {K\ > 100,000 nM) 
(Abramovitz et al., 2000). The chemical structures of PGE2 and prostanoid 
analogues are shown in Figure 1.1. 
4 
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1 
PGE2 ^^^COOH Sulprostone CO.NH.SO2.CH3 
O I O F 
6H 6H 6H 6H ^―^ 
17-PHENYL-PGE2 COOH SC-46275 
OH OH ^ U H 加 
FLUPROSTENOL COOH U-46619 C O O H 
-
F F 
HA / CF3 / 
- 6H OH \ ~ I 6H 
Ffgure 1.1 Chemical structures of PGE2 and some prostanoid analogues. 
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1.1.1.2 Agonists and antagonists 
In agreement with the ligand binding data, sulprostone, M&B-28767, GR-63799 are 
often used in pharmacological studies of EP3 receptors. As the ligand binding assays 
indicate, these agonists are also active on other prostanoid receptors. Moreover, 
there is still no compound reported to be effective in blocking EP3 receptor activation. 
Therefore, characterising EP3 receptor requires comparing the relative potencies of 
the agonists. In addition, EPi and TP receptor antagonists can be utilized to rule out 
EPi- and TP-mediated contractile effects on smooth muscles. 
On the other hand, there is another selective EP3 receptor agonist that has not been 
tested in a radioligand binding system with homogenous expression of EP3 receptors. 
SC-46275, originally found to be a gastric antisecretory prostaglandin analogue 
(Perkins et al” 1991)，is the most selective EP3 receptor agonist documented. 
Inhibition of electrically stimulated twitch contraction of the guinea-pig vas deferens 
is a typical EP3 action. SC-46275 had an EC50 of 0.04 nM, which was 40 and 135 
times more potent than sulprostone and PGE2 respectively. Its lack of activity — 
towards other EP subtypes is also an advantage over the not-too-selective ligands 
like sulprostone and M&B-28767 (Savage et al., 1993). -
Guinea-pig aorta is a vascular preparation that contains an EP3 contractile system. It 
showed the characteristic rank order of potency SC-46275 > sulprostone > PGE2 > 
17-phenyl-PGE2 (Jones et al., 1998). Equi-effective molar ratios (sulprostone 二 1.0) 
for SC-46275, PGE2 and 17-phenyl-PGE2 were 0.11，5.4 and 6.0 respectively. 
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1.1.1.3 Isoforms and signal transduction 
Multiple isoforms of the EP3 receptor of man, mouse, rat，rabbit, cow and pig have 
been cloned and expressed. The EP3 receptors, like the other prostanoid receptors, 
belong to the G-protein coupled receptor superfamily. It is evident that the variants 
are produced by alternative mRNA splicing (Kotani et al., 1997). The EP3 receptor 
isoforms differ in their carboxyl-terminal tails, with the amino acid sequences of the 
extracellular and transmembrane regions and the first ten intracellular amino acids 
residues of the carboxyl terminus being identical. In the following sections, 
characterisation studies of the mouse, bovine and human EP3 receptor isoforms will 
be used to illustrate the crucial role of the divergent carboxyl-terminal tails on the 
specificity of G-protein coupling, receptor desensitization and constitutive activity. 
1.1.1.3.1 Mouse — 
Mouse was the first species in which EP3 isoforms were detected. There are three 
isoforms, designated as EPsa, EPsp and EPsy. The isoforms were isolated from a 
mouse mastocytoma P-815 library by using a partial PGE receptor clone from a 
mouse lung cDNA library as a hybridization probe. The partial clone was detected 
by using PGR primers designed based on the third and sixth transmembrane domains 
of the human TP receptor (Sugimoto et al, 1992; Sugimoto et al., 1993; Irie et al., 
1993). The cDNAs of the three isoforms were expressed in COS-1 cells and their 
ligand-binding properties were shown to be the same. The rank order of potency was 
M&B-28767 > PGE2 = PGEi > ？GFja > PGD2 in competition binding assays with 
[3H]PGE2. 
7 
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EP3a and EPsp were the first isoforms of mouse EP3 receptor identified. They 
inhibited forskolin-induced cAMP accumulation with different efficiencies 
(Sugimoto et al, 1993). The IC50 of PGE2 and M&B-28767 for EP3a were three 
orders of magnitude lower than that for EPsp-expressing cells although the 
dissociation constants {K )^ of [^H]PGE2 binding to both isoforms were comparable 
(2.8 and 3.0 nM). In the presence of guanosine 5'0-(3-thiotriphosphate) (GTPyS), a 
non-hydrolysable GTP analogue, the K^ value of [^H]PGE2 for EPsa was decreased 
while that for EPsp was increased. Both effects were abolished by treatment with 
pertussis toxin and restored by the addition of G\2. Therefore, the opposite effects of 
the two isoforms were signalled via the same G protein, Gi, and the discrepancy in 
response to GTPyS was due to the difference in the carboxyl-terminus (Sugimoto et 
al., 1993). 
The same group of scientists reported the detection of the third isoform, EPsy. It was 
shown that M&B-28767 inhibited the elevation of cAMP level induced by forskolin 
in all the cells expressing the EP3 isoforms. The IC50 values for EPsa, EPsp and EPsy 
were 0.01, 1 and 3 nM respectively (Irie et al., 1993). The inhibitory effect of M&B-
28767 in the EPsy cells was abolished by pertussis toxin treatment. However, when 
the concentration of M&B-28767 was increased, forskolin-stimulated cAMP 
accumulation was potentiated. In addition, the M&B-28767-activated GTPase 
activity in the EPsy-expressing cell membrane was sensitive to both pertussis-toxin 
and cholera-toxin. Thus, unlike the EPsa and EPsp, which only couple to Gi protein 
to inhibit the formation of cAMP, EP^y also stimulates adenylate cyclase, probably 
via Ga (Irie et aL, 1993). 
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The role of the carboxyl-terminal tails in G protein coupling of the EP3 isoforms was 
further investigated. EPaa and EPsp, the two isoforms which couple exclusively to Gj, 
were found to exhibit a distinct difference in agonist-independent constitutive 
activity (Hasegawa et al., 1996). EPsa demonstrated marked agonist-independent 
inhibition of adenylate cyclase while EPsp did not show any constitutive effect. A 
mutant receptor (T-335) was also constructed. It had the same 335 amino acid 
residues common to the isoforms and was truncated at the splice site. The mutant 
receptor showed full constitutive activity in terms of inhibiting adenylate cyclase. 
Taken together, the authors concluded that the different carboxyl-terminal sequences 
conferred different degree of restraint on the constitutive activation of Gj (Hasegawa 
et al.’ 1996). 
The carboxyl-terminus of the EP3 isoforms also affects the process of receptor 
desensitization. It was found that EPsa and EPsp differed in sensitivity to agonist-
dependent desensitization (Negishi et al., 1993b). When EPsa was exposed^ to 0.1 
|j.M PGE2 for 30 minutes, the dose-response curve of PGE2-induced inhibition of 
forskolin-induced cAMP accumulation was shifted to the right in a parallel fashion 
by one order of magnitude; a further right-shift was found after 24 hours of exposure. 
Moreover, the maximal inhibition was reduced by 50%. On the contrary, neither 
treatment affected the dose-response relationship in the EPsp-expressin^cells. 
Radioligand binding assay was used as an indirect method to show that the agonist-
induced desensitization was due to a decrease in cell surface EPsa receptors. The 
extent of specific [^H]PGE2-binding was decreased with increasing exposure time, 
from 0 to 60 minutes, to 0.1 j^ M PGE2. The reduction in binding was significantly 
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blocked by concanavalin A, an agent shown to block sequestration of p-
adrenoceptors, hinting that the decrease in cell surface receptor was due to 
sequestration. The hypothesis was further verified. Negishi and co-workers found 
that, at pH 3.5, [^H]PGE2 could not bind to the receptor and even bound [^H]PGE2 
would be completely dissociated from the receptor in the membrane. It was shown 
that while almost all the [^H]PGE2 bound to EPsp was dissociated at pH 3.5，only 
about half of the [^H]PGE2 bound to EPsa was dissociated, suggesting that the 
ligand-bound EP3 receptors were internalized (Negishi et al., 1993b). 
Point mutations have been performed to investigate the structural requirements for G 
protein coupling. It was found that the amino acid residue Asp 318 in the seventh 
transmembrane domain of the mouse EPaa receptor was a key amino acid residue for 
G, coupling. Changing the negatively charged Asp_to the uncharged but polar Asn 
retained the ability of the receptor to associate with Gj but rendered it unable to 
activate the G protein. When the Asp-318 was replaced by a non-polar Leu, both the 
association and activation of Gj were inhibited. This suggested that the Asp 318 
residue was crucial in both the association and activation of G, which are two 
separate processes (Satoh et al, 1999). 
1.1.1.3.2 Cow 
Namba and co-workers used a fragment of the mouse EP3 receptor cDNA as a probe 
to screen a cDNA library of bovine adrenal medulla. Four isoforms of the EP3 
receptor were identified, namely EP3A, EP3B, EP3C and EP3D (Namba et al” 1993). 
They share the same amino-acid sequence up to the tenth intracellular amino acid 
10 
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after the seventh hydrophobic transmembrane domain. All four isoforms 
demonstrated specific [^H]PGE2 binding which was displaced by M&B-28767, PGE2 
and PGEi. The rank order of potency for these compounds was also identical for all 
four isoforms. However, the isoforms were shown to couple to a variety of G 
proteins. 
Surprisingly, only two of the four bovine isoforms coupled to Gj (Namba et al, 1993) 
whereas all the mouse EP3 isoforms were shown to couple to Gj (Trie et al., 1993; 
Sugimoto et al., 1993). ]VI&B-28767-induced phosphatidylinositol (Ptdlns) turnover 
in the EP3A- and EPso-expressing CHO cells was observed. The effects were found 
to be completely and partially reduced by pertussis toxin in EP3A- and EP3D-
expressing cells respectively (Namba et al, 1993). As there was a pertussis toxin-
insensitive component of the InsPs formation, EP3D appeared to be coupled to Gq 
protein as well as Gj. On the other hand, it was evident that three of the four 
isoforms were coupled to Gs. In cells expressing EPSB, EPSC and EP3D, M&B-28767 
induced GTP-dependent cAMP production which was not affected by pertussis toxin 
treatment and was inhibited by a specific anti-Gsa antibody (Namba et al, 1993). In 
a further study with cholera toxin-treated EPsc-expressing CHO cells, M&B-28767 — 
was shown to inhibit the GTPase activity of G�by increasing the apparent affinity of 
Go for GDP. The EP3 agonist had no effect on the GTPase activity of Gii，Gi2 and Gi3 
(Negishi et al., 1993a). 
To sum up, EP3A was found to couple to Gj only, EP3B to Gs, EPsc to Gs and G � a n d 
EP3D to Gi, Gs and Gq. Negishi and co-workers have located an arginine residue of 
the EP3D receptor which was essential for Gs coupling (Negishi et al., 1995). It is a 
11 
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conserved arginine residue within the seventh transmembrane domain in all the 
prostanoid receptors. It was demonstrated that the interaction between the negatively 
charged carboxylic acid of PGE2 and the positively charged arginine residue was 
necessary for the activation of Gg. When PGE2 was replaced by a ligand without a 
charged carboxylic acid moiety such as sulprostone, diminished adenylate cyclase 
stimulation via Gs activation was observed. On the other hand, point mutation of the 
arginine to an uncharged glutamine residue prevented the activation of Gs upon 
stimulation with all the agonists tested including PGE2. However, these two features 
were not required for Gj coupling (Negishi et al” 1995), 
1.1.1.3.3 Human 
To date, at least eight human EP3 isoforms have been characterised. In agreement 
with other species, the human isoforms are generated from mRNA splicing 
mechanisms. They are derived from a single human EP3 gene, PTGER3 (Kotani et 
al” 2000). Iff the early 1990’s，several groups of scientists started the cloning and 
expression study of human EP3 isoforms simultaneously. Different nomenclatures 
_ were used. Some of the isoforms cloned by different group turned out to have 
identical amino acid sequences. Therefore, the designations of the eight human 
isoforms do not appear to be as systematic as that of other species. The eight 
isoforms are known as EP3.1, EP3-11, EP3.111，EP3.1v, EP3.V，EP3.V1, EPse and EPsf 
(Adam et al., 1994; Kotani et al., 1997; Schmid et al, 1995). Consistent with the 
findings in other species, all the human EP3 isoforms only differ in their carboxyl-
terminal tail. The 359 amino-terminal residues, which form the extracellular and 
transmembrane regions and the first ten intracellular amino acid residues, are 
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identical in all the isoforms. EP3.1, EP3.11, EP3-111, EP3.1v, EP3.V, EP3.V1, EPse and EPsf 
are comprised of 390，388，365，374，402，393，393 and 425 amino acid residues 
respectively (Adam et al., 1994; Kotani et al., 1997; Schmid et al., 1995). 
All the isoforms were cloned from human uterus and kidney cDNA libraries or tissue 
samples from autopsy. [^H]PGE2 were demonstrated to bind specifically to all the 
isoforms. The rank orders of affinities of all the isoforms were comparable in 
competition binding assays with EP3 agonists and other prostanoids (Adam et al., 
1994; Kotani et al., 2000; Kotani et al., 1997; Schmid et al., 1995). 
It is evident that all the human EP3 isoforms are coupled to Gj. PGE2 and M&B-
28767 were shown to inhibit forskolin-induced cAMP accumulation (Kotani et al., 
2000; Kotani et al., 1995; Schmid et al., 1995). This inhibitory effect was abolished 
by pre-treatment of pertussis toxin (Kotani et al., 2000; Kotani et al., 1995; Schmid 
et al., 1995). 
Gq coupling may be involved in some of the isoforms. M&B-28767-induced InsPs 
elevation was observed in both EP3.1 and EPs.n-expressing COS-7 and CHO cells 
(Kotani et al., 1995). Moreover, An and co-workers reported that pertussis toxin did 
not abolish the M&B-28767-induced elevation of [Ca� .]/ in EP3.11, EP3.n1 and EP3.1v-
expressing cells and the source of [Ca^ "^ ]/ appeared to be an intracellular store (An et 
al., 1994). However, PGE2 increased [Ca2+]/ in baby hamster kidney (BHK) cells 
expressing EP3.1, EP3-11 and EP3.n1, which was blocked by pertussis toxin treatment 
(Schmid et al., 1995). The data for the latter part were not presented in the paper, 
thus, it is difficult to assess the extent of Gq involvement. 
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EP3.11 and EP3.1v were also shown to stimulate cAMP production upon agonist 
activation. Much higher doses of M&B-28767 were required to raise the cAMP 
level than to inhibit forskolin-induced cAMP accumulation (Kotani et al, 1995). 
It was found that the carboxyl-terminal structures of some isoforms are highly 
conserved among species. By comparing the amino acid sequence in the variable 
region, human EP3.1 is the homologue of the mouse EPsa and clone 74A of the rabbit 
EP3 receptor (Adam et al” 1994; Breyer et al” 1994). The human EP3-11 is the 
counterpart of mouse EPsy and bovine EPSD (Adam et al., 1994). 
1.1.1.4 Distribution 
EP3 receptors are the most widely distributed subtype of EP receptor (Coleman et al., 
1994). It reflects the diverse biological functions carried out by the subtype. 
Different biochemical techniques have been utilized to examine the expression of 
EP3 receptors in various tissues such as Northern hybridization and reverse 
transcription-polymerase chain reaction (RT-PCR). In human, EP3 mRNA has been 
detected in kidney, pancreas, small intestine, uterus, brain and aorta (Kotani et al., 
_ 1995; Regan et al., 1994; SchSiid et al., 1 9 9 5 ) . — 
It is also revealed that the mRNA expression of EP3 isoforms is-tissue-specific. In 
another words, the PTGER3 gene is differentially spliced in different tissues (Kotani 
et al, 1995; Schmid et al., 1995). All the eight human isoforms have been detected 
in kidney and uterus. EP3.1.1V are also expressed in the small intestine, pancreas, 
aorta and brain (Kotani et al., 1995; Schmid et al., 1995). Schmid and colleagues 
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reported the expression ofEPse and EP3.1 mRNA in the placenta and skeletal muscle 
respectively (Schmid et al., 1995). 
1.1.1.5 Knockout mice studies 
Receptor antagonists are classical tools for pharmacologists. The lack of specific 
receptor antagonist is a limitation to pharmacological experiments on EP3 receptors. 
Gene deletion provides another avenue to investigate the function of EP3 receptors in 
physiology and pathology. Audoly and co-workers carried out a series of knockout 
mice studies to examine the role of EP receptors in haemodynamic control, 
especially that in the kidney. It was observed that intravenous PGE2 transiently 
reduced the systemic blood pressure of the wild-type mice. This vasodepressor 
effect was prolonged in the EP3 -/- male mice while no difference was observed in 
the EP3 -/- females (Audoly et al, 1999). The function of EP3 receptor in renal 
haemodynamics was further investigated in male mice. A 43% increase in renal 
blood flow (RBF) and a 41% decrease in renal vascular resistance were observed in 
the EP3 -/- mice. The RBF was measured using a miniaturized ultrasound flow 
transducer (Audoly et al., 2001). Moreover, high doses of PGE2 (250 - 500 ng) 
injected directly into the renal artery caused more pronounced vasodilation in EP3 -/-
mice than in the wild-type. These findings have provided important information on 
— the role of EP3 receptors in mediating vasoconstriction in the kidney. 
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1.1.2 EPi receptors 
1.1.2.1 Ligand binding properties 
In contrast to the EP3 receptor, PGE2 displayed the lowest affinity for the 
recombinant EPi receptors from man (Abramovitz et al., 2000)，rat (Boie et al., 1997) 
and mouse (Kiriyama et al, 1997) among the EP receptor subtypes, with K^ values 
of 25, 24 and 21 nM respectively. Table 1.2 shows the K\ values of various 
prostanoid analogues for recombinant EPi receptors of human, rat and mouse. 
Table 1.2 Competition for radioligand binding to recombinant EPi receptors 
Species Human Rat Mouse 
Cell line HEK 293 ( E B N A ) H E K 293 (EBNA)“""“CHO 
Reference (Abramovitz et al., (Boie et al., 1997)~(Kiriyama ^ 
‘ 2000) al., 1997) 
Ligands K�values (nM) 
P G E 2 ^ [ 2 2 R ^ -
P G E I N T % ^ 
ILOPROST R R I L S ^ 
17-Phenyl-PGE2 N T “ 25 14 
Sulprostone 107 ^ 
Enprostil ^ NT 
NT: not tested. [ 'HJPGEZ was the radioligand. 
All the agonists that have high affinity for EPi receptor also bind to other prostanoid 
receptors with comparable affinities. For example, 17-phenyl-PGE2 has an affinity 
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comparable to that of PGE2 for EPi while it binds reasonably well with EP3 (Boie et 
al., 1997; Kiriyama et al., 1997). However, there are certain clear trends for EPi 
receptor specificity. PGEi has a slightly lower affinity than PGE2 and 17-phenyl-
PGE2 is more potent than sulprostone at EPi. At EP3, PGE! and PGE2 are equally 
potent and sulprostone has a higher affinity than 17-phenyl-PGE2. Furthermore, 
iloprost, a prostacyclin analogue, binds to EPi with high affinity similar to PGE2. It 
is a characteristic that distinguishes EPi receptor and other EP receptor subtypes. 
Several antagonists have been developed for the EPi receptor subtype. SC-51322 
demonstrated the highest affinity among other antagonists tested in the human EPi-
expressing HEK 293 cells, with K, of 13.8 nM (Abramovitz et al., 2000). AH-6809 
and SC-19220 only weakly bound to the rat EPi receptor, with K�values of 1,300 and 
26,400 nM respectively (Boie et al., 1997). Species difference might exist; both 
compounds displayed no affinity for the mouse EPi receptor (Kiriyama et al, 1997). 
Another antagonist, SC-51089 showed weak affinity for the human EPi receptor with 
Ki of 1,332 nM (Abramovitz et al., 2000). ONO-DI-004 is a selective EPi antagonist 
recently developed. In mouse EP-expressing CHO cells, ONO-D1-004 was shown to 
一 be a selective ligand for the EPi subtype. However, the potency was relatively low 
with Ki of 150 nM (Suzawa et al, 2000). 
1.1.2.2 Agonists and antagonists 
1.1.2.2.1 Agonists 
As mentioned earlier, there is no highly selective agonist for the EPi receptor 
subtype. Iloprost, is a potent agonist for EPi. However, it appeared to be a partial 
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agonist for EPi receptors in isolated bullock iris sphincter, rat stomach fundus strip 
and guinea-pig trachea with EC50 values of 27，16 and 27 nM respectively (Dong et 
al” 1986). In the same study, ICI-80205 and 16,16-dimethyl PGE2 were found to be 
more potent than PGE2 for the EPi receptors on bullock iris sphincter and rat 
stomach fundus strip. However, these two agents were also observed to be potent 
agonists for EP3 (Lawrence et al” 1992) and TP receptors (Jones et al., 1982). 
The selectivity of 17-phenyl-PGE2 for EPi receptor over EP3 receptor is less than 
ten-fold (Lawrence et al.，1992) and binding data described above. However, if it is 
used together with sulprostone which has greater potency for EP3 than for EP!，EPi 
can be distinguished from EP3. In addition, the use of EPi antagonists and the more 
selective EP3 agonist, SC-46275, can increase the security of the characterisation. 
1.1.2.2.2 Antagonists 
AH-6809 and SC-19220，two of the earlier characterised compounds are weak EPi 
antagonists. Both compounds now have a limited role in characterising EPi receptor-
containing preparations, in view of the availability of more suitable compounds. SC-
19220 has poor aqueous solubility (Coleman et al., 1990). Moreover, it has low 
affinity for the recombinant human (Abramovitz et aL, 2000) and rat EPi receptors 
(Boie et al” 1997)，with K, values of 1,332 and 26,400 nM respectively. AH-6809, 
although it is more potent than SC-19220，has considerable blocking activity at DP 
receptors (Coleman et al., 1985). In recently reported reporter gene assays of EPi 
and DP receptors, the antagonism of AH-6809 was observed to be stronger at the DP 
receptor than the EPi receptor (Durocher et al., 2000). Moreover, AH-6809 was 
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shown to be 97% protein bound in the presence of 4% bovine serum albumin, which 
hampered its use in in vivo testing. 
SC-51089 and SC-51322 are dibenzoxazepines with both EPi receptor antagonist 
and analgesic properties. They have more selective binding profiles than AH-6809 
(Boie et al.’ 1997). SC-51322 was shown to be a potent antagonist with a reported 
pKe value of 8.8 in reporter gene assay in HEK 293 EBNA cells expressing EPi 
receptors (Durocher et al., 2000), The pKe value of SC-51089 in the same assay was 
6.9. 
ONO-8711 and ONO-8713 are two newly developed selective EPi antagonists. 
They have been demonstrated to inhibit PGE2-induced rise in [Ca^ "^ ]/ in mouse and 
human EPi-expressing CHO cells. The respective IC50 values of ONO-8711 and 
ONO-8713 in mouse EPi-expressing cells were 0.21 and 0.46 nM and that in human' 
EPi-expressing cells were 50 and 140 nM (Watanabe et al., 2000; Watanabe et al., 
1999). ONO-8711 and ONO-8713 were shown to suppress azoxymethane (AOM)-
induced aberrant crypt foci (ACFs) formation in mice by blocking EPi receptor 
(Watanabe et al., 2000f Watanabe et al., 1999). ACFs are putative preneoplastic 
lesions in the colon of mice. The EPi receptor had been shown to be involved in 
colon carcinogenesis from studies on mice lacking EPi r^eptors (Watanabe et al, 
1999). 
1.1.2.3 Structure-a ctivity re la tionship 
Ungrin and colleagues have recently carried out a structure-activity relationship 
(SAR) study of an extensive list of prostaglandins and analogues for the recombinant 
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human EPi receptor (Ungrin et al, 2001). They generated quantitative data of 
affinity and potency by using radioligand binding assay and automated aequorin-
based calcium functional assay, respectively. It was found that the stereochemistry of 
the hydroxyl group atC-15 was extremely crucial for PGE2 to act on EPi receptor. A 
reduction in potency of 870-fold occurred on changing the 15(S) configuration to a 
15(R) one. The configuration of the hydroxyl group at C-11 was also demonstrated 
to be important for both affinity and potency. The potency was significantly reduced 
by removing or modifying the hydroxyl group to a keto group. Changing the 
stereochemistry at the C-11 position could also impair EPi receptor activation 
(Ungrin et al., 2001). 
Increased potency can be brought about by modifying the co-chain terminus of PGE2. 
Although the mechanism of the effect has not been rationalized, 17-Phenyl-PGE2 
(Figure 1.1) was found to have raised potency, compared with PGE2 simply by 
substituting the tail with a phenyl group (Ungrin et al., 2001). 
Apart from sulprostone and enprostil, it was shown that esterification of the 
carboxylic acid moiety at C-1 drastically reduced the compound's potency at the 
human EPi receptor. The authors suggested that the retention of potency of the two 
compounds might be due to the presence of a phenoxy substitution at C-16 (Ungrin 
et a/.，2001). 
1.1.2.4 Signal transduction 
Mobilization of Ca^ "^  is believed to be the effector mechanism of EPi activation, but, 
scientists disagree on the source of the Ca^^. Watabe and co-workers demonstrated 
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that in mouse EPi-expressing CHO cells, [Ca^ "*"]/ was increased by PGE2. The effect 
was blocked by removing extracellular Ca^ "^  (Watabe et al., 1993). This agrees with 
earlier findings by Creese and Denborough. They found that contractions produced 
by PGE2 on guinea-pig trachea were dependent on extracellular Ca^ "^  (Creese et al., 
1981). 
Shibuya and co-workers have presented evidence to suggest that an EPplike receptor 
mediates PGE2-induced Ca^ "^  release from intracellular cafFeine/ryanodine-sensitive 
stores in the bovine adrenal medulla (Shibuya et al., 1999). PGE2-elevated [Ca^ "^ ]/ 
was completely abolished by pre-treating the cultured cells with 10 |iM ryanodine 
and 10 mM caffeine but was not affected by 50 j^ M cinnarizine, a selective blocker 
of InsPj-induced Ca^ "^  release. Therefore, Ca^^ appeared to be released from the 
ryanodine/caffeine-sensitive store but was not mediated by InsP�. This is further 
supported by treating the cells with U-73122, a PLC inhibitor which was able to 
block the InsPs generation but failed to reduce the [Ca!.]/ elevation. 17-Phenyl-
PGE2 (EP1/EP3) and sulprostone (EP1/EP3) was capable of raising in the 
bovine adrenal medulla but misoprostol (EP2/EP3) showed little response. Moreover, 
SC-51322, a selective EPi antagonist, inhibited the PGErinduced [Ca^ "^ ]/ increase. 
Therefore, the increase in [Ca�.]/ was mediated mainly by EPi via a mechanism that 
was not coupled to the Gq/InsPs pathway. _ 
This finding is novel since Ca^ "^  mobilization via G protein-coupled receptor is 
normally thought to be involving the Gq/InsPs pathway. In fact, although not further 
verified, the uncoupling of InsPs and [Ca ] i elevation was already suspected in the 
study by Watabe et al mentioned above. From the representative trace, only 20% 
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increase of Ptdlns turnover was observed with more than 150% increase in [Ca^^]/ 
(Watabe et al., 1993). 
A variant of the EPi receptor has been isolated from a rat uterus cDNA library 
(Okuda-Ashitaka et al., 1996). The first 951-bp of the rat EPi-variant was identical 
to the rat EPi receptor. However, for the EPi-variant, at nucleotide position 952， 
where it was normally spliced, translation continued. As there was an in-frame stop 
codon, TAG, at position 1,099, a 366-amino acid variant was produced. The variant 
had a longer third extracellular loop followed by a seventh transmembrane domain-
like structure (VII’). No intracellular carboxyl terminal tail was attached to VII'. 
The variant had similar ligand binding properties to the rat EPi receptor. However, it 
did not couple to second messengers upon binding. PGE2-induced elevation of 
[Ca ]/ mediated by EPi receptor was diminished by stable co-expression with the 
EPi-variant. When co-expressed with native EP4 receptor, EPi was shown to 
suppress the EP4-induced cAMP formation. The mechanism of the variant in 
attenuating the other receptor's signal transduction is not clear. Breyer and co-
workers speculated that the variant might form dimers with another receptor, 
rendering it less effective (Breyer et al., 2001). 
1.1.2.5 Distribution 
In contrast to the EP3 receptor, the EPi receptor has restricted distribution. The EPi 
receptor is found in the trachea, gastrointestinal tract, uterus and bladder of guinea-
pig (Coleman et al, 1994). In mouse, Northern blot analysis revealed that mRNA of 
EPi was expressed mainly in kidney and lung (Watabe et al.，1993). Using a DNA 
probe common to both rat EP! receptor and its variant, Okuda-Ashitaka and co-
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workers reported abundant expression of the receptors in kidney and lung. Weaker 
signals were observed from the colon, spleen and thymus (Okuda-Ashitaka et al., 
1996). Rat gastric and intestinal muscle layers were also found to express EPi 
rtiRNA (Ding et al., 1997). In human, high expression of EPi receptor in ocular 
tissues was detected by using an EP!-specific antibody. The epithelia of the cornea, 
conjunctiva, lens, ciliary body, trabecular endothelial cells, vascular endotheilial cells 
of the iris, retinal ganglion cells and photoreceptor cells were found to express EPi 
receptor (Schlotzer-Schrehardt et al., 2002). Human myometrium was also found to 
express EPi receptors (Senior et al” 1991). 
1.1.3 FP receptors 
1.1.3.1 Ligand binding properties 
FP receptors have been cloned from human (Abramovitz et al” 1994)，mouse 
(Sugimoto et al., 1994)，cow (Sakamoto et al., 1994)，rat (Lake et al., 1994) and 
sheep (Graves et al., 1995) tissues. In human FP-expressing HEK 293(EBNA) cells, 
[^H]PGF2a binding was displaced by FP agonists with a rank order of cloprostenol > 
fluprostenol = latanoprost (free acid) = PGF2a > latanoprost (isopropyl ester). Their — 
respective Ki values were 0.47, 2.3, 2.8, 3.2 and 555 nM (Abramovitz et al, 2000). 
Although cloprostenol was the most potent ligand, it is less selective than 
fluprostenol and latanoprost (free acid). Fluprostenol and latanoprost (free acid) also 
had better selectivity profiles than the natural ligand, PGF2a which showed affinity 
for EP3 and EP4 receptors. Cloprostenol also bound to human EP3 receptor with K\ 
value of 4.4 nM (Abramovitz et al., 2000). When compared with other prostanoids 
and analogues, the rank order for displacing [^H]PGF2a binding was PGF2a = 
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fluprostenol > PGD2 > PGE2 > U-46619 > iloprost with IC50 values of 2.8, 3.5，7.0， 
85，146 and 1200 nM respectively (Abramovitz et al., 1994). This ranking is similar 
to those obtained from the recombinant bovine FP receptor. In the bovine FP-
expressing COS-7 cells, the rank order of potency was PGF2a > PGD2 > PGE2 > 
STA2 (Sakamoto et al., 1994). Both U-46619 and STA2 are stable TP receptor 
agonists. The mouse FP receptor showed a slight difference with PGE2 being less 
potent than STA2. The rank order was PGF2a > 9a,llp-PGF2 > PGFia > PGD2 > 
STA2 > PGE2 > iloprost (Sugimoto et al； 1994). Kiriyama and co-workers 
demonstrated that a variety of non-FP ligands had affinities for the mouse FP 
receptor expressed in CHO cells. The following rank order of potency was obtained: 
PGF2a = fluprostenol > PGD2 = 17-phenyl-PGE2 > STA2 = I-BOP = PGE2 = M&B-
28767 > 16,16-dimethyl-PGE2 = sulprostone > U-46619 = 19R(OH)-PGE2 with Ki 
values of 3.4，3.8，47，60，97，100，100，124，350，580，1000 and 1000 nM 
respectively (Kiriyama et al., 1997). 
1.1.3.2 Structure-activity relationship 
Synthetic modifications of PGF2a were used to investigate the structural 
requirements necessary for substrate- binding to FP receptor. Schuster and co-
workers revealed that the C-1 carboxylic acid group was essential for PGF2a to bind 
to the FP receptor. The binding affinity was reduced—by substituting acylsulfonamide 
or tetrazole for the carboxylic acid group. Both substituents have pKa values similar 
to carboxylic acid (pKa 4.5) but are bulkier. Replacing the carboxylic acid moiety 
with neutral groups such as esters also diminished the binding affinity. Changing the 
stereochemistry of the 15-hydroxyl group from (S) to (R) caused a significant 
reduction in affinity. However, substitution for the 15-hydroxyl group and insertion 
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of cyclic substituents in the co chain did not alter the binding affinity to a large extent 
(Schuster et al.’ 2000). 
1.1.3.3 Agonists and antagonists 
Based on its potency and selectivity, fluprostenol which was synthesized in the 
1970’s，has been regarded as a compound with diagnostic power in determining the 
existence of FP receptors in a given tissue (Coleman et al., 1990). Fluprostenol has 
been reported to potently contract the dog and cat iris sphincter muscle and the non-
pregnant human myometrium which possess FP receptors (Coleman et al., 1981; 
Dong et al” 1982; Senior et al, 1991; Senior et al., 1992). 
Latanoprost, another selective FP receptor agonist, was developed more recently. It 
is now used in the clinic for raised intra-ocular pressure (lOP) in open-angle 
glaucoma and ocular hypertension (BNF). Latanoprost is a prodrug with an 
isopropyl ester in its a chain which is then converted to free acid in vivo. The free 
acid form is much more active at the FP receptor than the isopropyl ester (Breyer et 
al” 2001). Bimatoprost, travoprost and unoprostone are other FP receptor agonists 
developed for treating raised lOP. Whether bimatoprost and unoprostone reduce lOP _ 
via the FP receptor has been a controversial issue. They did not show specific 
binding in FP receptor containing preparations (Bhattacheijee et al” 2001; 
Woodward et a/., 2001). 
AL-8810, a novel analogue of PGF2a, has been introduced by Griffin and colleagues 
recently as a selective FP receptor antagonist (Griffin et al., 1999). This compound 
was discovered to be a partial agonist at FP receptors. Moreover, AL-8810 was 
25 
Chapter 1 - Introduction 
incapable of inhibiting cAMP formation coupled to EP2, EP4, DP and IP receptors 
and it only inhibited PLC activation mediated by TP receptor at 100 AL-8810 
displayed about 20% efficacy at the endogenous FP receptors in both Swiss mouse 
3T3 fibroblasts and A7r5 rat vascular smooth muscle cells. The compound showed 
characteristics of a competitive antagonist in that it shifted the dose-response curve 
of fluprostenol to the right in a parallel manner. The respective pA2 values of AL-
8810 determined with Swiss mouse 3T3 fibroblasts and A7r5 rat vascular smooth 
muscle cells were 6.39 and 6.68 (Griffin et al., 1999). AL-8810 was also shown to 
antagonize the intracellular Ca^ "^  mobilization effects of travoprost acid, bimotoprost 
acid, bimotoprost and unoprostone in FP-expressing A7r5 cells (Kelly et al., 2003). 
1.1.3.4 Isoforms and signal transduction 
Activation of PLC via Gq and subsequent Ptdlns turnover and Ca^ "^  mobilization are 
the major mechanisms identified for FP receptor (Coleman et al., 1994; Nanimiya et 
al., 1999). PGF2a and fluprostenol were demonstrated to raise [Ca^ "^ ]/ in Xenopus 
oocytes expressing human FP receptors (Abramovitz et al., 1994). Griffin and 
colleagues have demonstrated that both Swiss 3T3 and A7r5 rat aortic smooth 
muscle cell lines—contain functional FP receptors (Griffin et al., 1998; Griffin et al., 
1997). InsPs formation and elevation of were observed with FP receptor 
agonists and the Ca^"^ mobilization was dependent on InsPs since U- 7 3 1 2 2， a PLC 一 
inhibitor, inhibited fluprostenol- (Griffin et al., 1998) and cloprostenol-induced 
[Ca2+]/ elevation (Griffin et al” 1997). The potencies for mediating these signalling 
events correlate well with their binding affinities. The rank order of potency in 
stimulating InsP turnover in A7r5 cells was cloprostenol > 16-phenoxy P G F 2 a � 1 7 -
phenyl PGF2a > fluprostenol > PGF2a > PhXA85 with EC50 values ranged from 0.84 
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to 43.5 nM (Griffin et al., 1998). Recently, Milne and Jabbour (2003) also observed 
PLC-dependent InsPj turnover by PGFza in the human endometrium. 
Interestingly, the signal transduction activities in the A7r5 cells were significantly 
inhibited by removing extracellular calcium. It was evident that influx of 
extracellular Ca^ "" was dependent on PLC (Griffin et al., 1998). However, the 
mechanism was not further investigated. 
Two FP receptor isoforms, named FPA and FPB, resulting from alternative mRNA 
splicing have been cloned from a mid-cycle ovine large cell corpus luteum library 
(Pierce et al” 1997). Similar to the EP3 receptor isoforms, the ovine FP receptor 
isoforms possessed identical amino acid sequence in the extracellular and 
transmembrane domains and only differed from the tenth amino acid residue in the 
carboxyl-terminal tail. FPA continues for 46 amino acids while FPB has only one 
more amino acid residue after the splice point. 
Both isoforms showed nearly identical rank order of binding affinity. 17-Phenyl-
—trinor-PGF2a was the most potent unlabelled ligand, followed by PGFza and then 
fluprostenol in displacing 17-[^H]phenyl-trinor-PGF2a. PGD2 and PGE2 were also 
capable of-displacing 17-[^ H]phenyl-trinor-PGF2a binding. Both isoforms when 
expressed in COS-7 cells were found to stimulate Ptdlns turnover to the same 
maximum level upon PGF2a activation. However, the basal level of InsPs 
accumulation of FPA was about 40% higher than that of FPB. Both isoforms 
displayed agonist-independent constitutive InsPs accumulation, with FPB showing 
higher level of constitutive activity (Pierce et aL, 1997). On the other hand, Pierce 
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and co-workers also found that cell morphology changes in the ovine FPA- and FPB-
expressing HEK 293(EBNA) cells were dependent on Rho although the signalling 
pathway was not elucidated (Pierce et al” 1999). 
Srinivasan and co-workers recently reported different internalization characteristics 
of the two ovine FP receptor isoforms. By using FLAG-tagged FP receptor isoforms 
and anti-FLAG antibodies, the localization of the isoforms was visualized using 
immunofluorescence microscopy technique. Agonist-induced internalization was 
observed for FPA receptor. It was suggested that PKC was involved in the agonist-
induced internalization of FPA since Go 6976，A PKC inhibitor prevented the 
internalization. On the other hand, FPB receptors internalized in the absence of 
PGF2CX. This constitutive activity was independent of the function of PKC as it was 
affected by neither Go 4976 nor PMA, a PKC activator (Srinivasan et al., 2002). 
The discovery of an isoform for the bovine FP receptor has been described by Ishii 
and Sakamoto. The new isoform, designated FPa receptor, was coded from the same 
gene as the original bovine FP receptor and was resulted from alternative mRNA 
splicing (Ishii & Sakamoto，2001). It noticeably resembles the EPi-variant in the-
sense that it also lacks the carboxyl-terminal tail. The splice site appeared to be in 
the middle of seventh transmembrane domain and the FPa had a unique sequence of 
28 amino acids following that. PKC assay was performed for both isoforms. 
Consistent with the common understanding that FP receptor couples to Ca^ "^  
mobilization, PKC activity in the bovine FP-expressing COS-7 cells was 
significantly raised after PGF2a (1 fiM) stimulation. However, PKC activity was 
unaffected by activating the FPa isoform (Ishii & Sakamoto, 2001). Furthermore, 
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when co-expressing with FP receptor, FPa demonstrated a tendency to attenuate the 
FP-induced PKC activation. The situation is analogous to the rat EP!-variant 
described in section 1.1.3.4. 
1.1.3.5 Distribution 
In situ hybridization analyses revealed that FP receptor mRNA was highly expressed 
in luteal cells of corpus luteum of mouse (Sugimoto et al., 1994) and bovine tissues 
(Sakamoto et al.’ 1994). The expression of FP mRNA in human (Milne et al,, 2003) 
and mouse (Hasumoto et al., 1997) endometrium was found to temporally regulated. 
The receptor was also found to be expressed in mouse kidney, heart, stomach and 
lung (Sugimoto et al., 1994). 
Functional FP receptors were found to exist on the non-pregnant human (Senior et al., 
1992) and rat myometrium (Whalley et al., 1980). In cats and dogs, FP receptors 
were found to be on airway smooth muscle mediating its contraction (Coleman et al” 
1994). — 
FP receptor agonists and pro-drugs, given as eye drops, are effective in reducing 
increased intraocular pressure, indicating that FP receptors are present in ocular 
tissues. In fact, in the corneal epithelium,_FP receptor protein and mRNA were 
found to be highly expressed using immunohistochemistry and RT-PCR respectively. 
The receptor was also found in the ciliary epithelium, stromal cells and smooth 
muscle cells of the iris (Schlotzer-Schrehardt et al” 2002). 
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1.1.4 TP receptors 
1.1.4.1 Ligand binding properties 
Compared with other prostanoid receptors, there are many receptor agonists and 
antagonists for TP receptor. Radioligands available include [^H]U-46619, 
[^H]U-44069, [^H]13-azaprostanoic acid, ‘ 1 3 - a z a , 16-p-hydroxphenylpinane TxA?， 
[^H]SQ-29548, [^H]GR-32191 and The first two are agonists and the 
latter five are antagonists. Their Kd values range from 0.2 to 100 nM (Coleman et al., 
1990). Many ligand binding studies were done on membrane preparations from 
platelets, vascular and bronchial smooth muscle. 
I-BOP was reported to have 90% specific binding to washed human platelets, which 
was more than that of U-46619 and U-44069 (Morinelli et al., 1989). In the same 
preparation, the rank order—of potency in displacing was I-BOP > ONO-
11113�9，11 -azo-PGH2 > U-46619. 
The human TP receptor has been cloned (Hirata et al., 1991). In the human TP-
expressing COS-7 cells, the rank order of potency in displacing [^H]S-145 was S-145 
> ONO-3708 > STA2. PGD2, PGF2a, PGE2 and PGI2 also bound to the TP receptor “ 
with weak affinities (Hirata et al., 1991). Abramovitz and co-workers performed 
ligand binding assay on HEK 293(EBNA) cells expressing human TP and other 
prostanoid receptors. SQ-29548 was found to be not only potent but also selective 
for the TP receptor (Abramovitz et al.’ 2000). U-46619, a commonly used TP 
receptor agonist, was found to have Ki value merely 7 times higher for the FP 
receptor (241 nM) than the TP receptor (35 nM) (Abramovitz et al., 2000). 
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Following the cloning and expression of the human TP receptor, the mouse TP 
receptor was also cloned (Namba et al., 1992). The K^ value of [^H]S-145 was 3.3 
nM for the mouse TP receptor expressed in COS-1 cells. The binding of [^H]S-145 
was displaced in the rank order of S-145 > STA2 > U-46619 > PGD2 > PGFza = 
PGE2. Kiriyama and co-workers later used some additional ligands in CHO cells 
transfected with mouse TP receptor with the rank order of I-BOP = S-145 > GR-
32191 =SQ-29548 = STA2 > U-46619 (Kiriyama et al, 1997). 
1.1.4.2 Agonists and antagonists 
TXA2 itself has a half-life of about 30s at 37°C and pH 7.4，making its quantitative 
pharmacological study difficult (Coleman et al,, 1990). U-46619, a stable analogue 
of PGH2, is the most widely used TxA2 mimetic. In human platelet-rich plasma, a 
classical preparation for testing the TP receptor system in vitro, U-46619 induces 
complete and irreversible aggregation (Coleman et al., 1990). However, U-44069, 
an isomer of U-46619, is a partial agonist for the TP receptor and only induces 
reversible aggregation (Armstrong et al., 1995). I-BOP and STA2 were shown to 
produce human platelet aggregation 10 times (Morinelli et al, 1989) and 3 times 
(Jones et al, 1987) more potently than U-46619 respectively. EP-171, another TP 
agonist, was about 90 times more potent than U-46619 in causing platelet 
— aggregation (Jones et al” 1989). However, EP-171 was exceedingly slow acting 
compared with other TP receptor agonists. The slow kinetics was suggested to be 
due to restricted diffusion in the extracellular space arising from the high affinity of 
the TP receptor interaction rather than the lipophilicity of the ligand (Jones et al, 
1989). 
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Apart from platelet aggregation, contractions of isolated vascular preparations like 
the dog saphenous vein and rat or rabbit aorta, and contraction of guinea-pig trachea 
are also commonly used tests for the TP receptor system. 
In contrast to other prostanoid receptors, many blocking agents with diverse range of 
structures are readily available for the TP receptor. GR-32191 (vapiprost), SQ-
29548，ICI-192605, L-655240 and BAY u 3405 are potent TP receptor antagonists 
with pA2 values reported to be above 8. AH-19437, GR-32191, EP-045，EP-092, 
ICI-192605，BAY u 3405 and SQ-29548 are selective TP receptor antagonists that 
are devoid of activity at other prostanoid receptors (Abramovitz et al., 2000; 
Coleman et al” 1994). AH-23848 was observed to have sufficient antagonist activity 
at EP4 receptor (Coleman et al,, 1994) to allow its use for distinguishing EP2 and EP4 
receptors in functional systems. 
1.1.4.3 Isoforms and signal transduction 
The first cloned TP receptor, a protein of 343 amino acids, originated from hum面 
placenta (Hirata et al” 1991). An alternatively spliced variant was later isolated from 
a human endothelial library (Raychowdhury et al., 1994). The ibrmerly discovered 
placental TP was subsequently designated as TPa and the endothelial variant was 
designated as TPp. TPp has its first 328 amino acids identical to TPa. After the 
splice site, it is continued with a further sequence of 79 amino acids which was 
distinct from TPa. Specific [^H]SQ-29548 binding was demonstrated in CHO cells 
expressing both endothelial and placental TP receptors with K\ values of 10.0 and 
12.4 nM. U-46619 and I-BOP activation of both isoforms was shown to induce 
[Ca2+]/ elevation, which was blocked by SQ-29548 (Raychowdhury et al, 1994). 
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It has been known that TP receptor agonists caused Ca2+ mobilization in platelet and 
vascular smooth muscle cells (Breyer et al, 2001; Coleman et al, 1994). There are a 
few lines of evidence supporting the involvement of Gq protein in TP receptor-
mediated effects. Shenker and co-workers showed that the rank of potency in 
stimulating GTPase activity in human platelet membrane was I-BOP > U-46619 = U-
44069. I-BOP-activated GTPase activity was shown to be inhibited by an ccq/n-
selective antibody, QL (Shenker et al., 1991). On the other hand, Knezevic and 
colleagues, by using ligand (SQ-31491 )-affinity chromatography method, found that 
Gqa sub units were associated with the eluted platelet TP receptors (Knezevic et al” 
1993). In addition, Kinsella and co-workers showed that [Ca^ "^ ]/ was raised in HEK 
293 cells transfected with TPa upon U-46619 activation when the cells were co-
transfected with Gq/ii. Ca^ "^  mobilization did not occur when the cells were 
expressing TPa but not Gq/n, indicating a functional relationship between TP receptor, 
Gq/ii and raised [Ca "^"]/ (Kinsella et al” 1997). 
Other G proteins have been identified in the signal transduction pathways of TP 
receptors. With the techniques of agonist-dependent photolabeling of G proteins _ 
_ with [a-32p]GTP azidoanilide and immunoprecipitation of the photolabeled G-
proteins, Offermanns and co-workers demonstrated that U-46619-activated TP 
receptor coupled to G12 and Go proteins in human platelet membranes (Offermanns 
et aL, 1994). On the other hand, when partially purified TP receptors were 
reconstituted with Gi2 in phospholipids vesicles, the binding of GTPyS to Gi2 was 
stimulated by STA2 binding to the TP receptors. The GTPase activity of the Gi2 was 
also shown to be raised by the STA2-liganded TP receptor, suggesting that the 
receptor was functionally coupled to Gi2 (Ushikubi et al., 1994). 
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Both TPa and TPp isoforms overexpressed in HEK 293 cells underwent 
phosphorylation upon U-46619-stimulation (Habib et al, 1997). Pre-treating the 
cells with about 100 |aM U-46619 caused desensitization assessed by InsPs formation. 
The extent of phosphorylation and desensitization was shown to be similar for both 
isoforms (Habib et al., 1997). However, Parent and colleagues detected differences 
in agonist-induced and tonic internalization between the two TP receptor isoforms 
expressed in HEK 293 cells (Parent et al., 2001; Parent et al” 1999). ELISA analysis 
was used to quantify receptor internalization. TPa was not internalized when 
challenged with a high dose of U-44619 for 3 hours. TPp, on the contrary, underwent 
internalization upon agonist stimulation (Parent et al, 1999). This agonist-induced 
internalization process was dependent on dynamin, GRK and arrestin. This 
phenomenon was reproducible in other cell types including P388D1, A431, 
MiaPaCA and CHO, transfected with the two isoforms. It was soon found that TPp 
underwent tonic internalization in the absence of agonist (Parent et al., 2001). 
Truncation and site-directed mutagenesis studies were performed to map the motif 
that was responsible for the process. The motif consists of a stretch of 3 amino acids 
in between-a tryptophan and a bulky hydrophobic residue in the proximal portion of 
the carboxyl-terminal tail. Introducing this motif in TPa also caused this isoform to 
internalize. There was also evidence to suggest that the internalized TPp but not new 
receptors redistributed to the cell surface. The authors suggested that this might be a 
mechanism to preserve agonist sensitivity (Parent et al., 2001). 
1.1.4.4 Distribution 
As reflected from their biological function, TP receptors are widely distributed in 
vascular smooth muscles and platelets. They are also present in myofibroblasts and 
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epithelium of gastrointestinal tract (Coleman et al., 1994). Using Northern blot 
analysis, mouse TP receptors mRNA was found to be expressed at highest level in 
the thymus. Ushikubi and co-workers later found that in the thymus, TP receptor 
was found to be expressed as abundantly in the immature thymocytes as in platelet 
(Ushikubi et al” 1993). The receptor was also expressed in spleen, lung, kidney, 
heart, uterus and brain (Namba et al., 1992). Abe and co-workers examined the TP 
receptor distribution in rat kidney using in situ hybridization. It was found that TP 
receptor mRNA was present in smooth muscle cells of renal arterioles, glomeruli and 
transitional cell epithelium of the renal pelvis (Abe et al.’ 1995). From these studies, 
it is speculated that apart from mediating excitatory events in the vasculatures, TP 
receptors may also play a part in the immune system. 
/ -
35 
Chapter 1 - Introduction 
1.2 Role of Ca2+ in vascular smooth muscle contraction 
1.2.1 Ca2+ as second messenger 
Although Ca2+ sensitization has been the focus of attention for recent years, 
fluctuations in concentration of intracellular Ca^^ ([Ca^" ]^/) is still a major regulation 
of the contractile state of smooth muscle cells. The conventional theory that Ca^ "^  
complexes with calmodulin and activates myosin light-chain kinase which in turn 
phosphorylates the regulatory light chain of myosin at Ser 19 causing actin to 
activate myosin ATPase and the subsequent muscle contraction, still holds. Ca^ "^  is 
an important second messenger for the initiation of excitation-contraction coupling. 
In vascular smooth muscle, elevation of results in vasoconstriction. There are 
two main ways to raise the global cytoplasmic [Ca^ "^ ], namely Ca^^ influx from 
extracellular solution and intracellular Ca^ "^  release. 
一 1.2.1.1 Ca^^ entry 
There are different types of channels through the plasma membrane which allow 
Ca2+ to enter the cell. Voltage-dependent calcium channels (VDCCs) provide the 
main path. The L-type calcium channel is a voltage-dependent calcium channel 
commonly seen in smooth muscle cells. At resting membrane potentials, these 
channels are inactivated and they are opened upon more positive membrane 
potentials during depolarization. These channels have been shown to have a high 
rate of Ca^^ permeation at physiological Ca^ "^  concentration and membrane potentials 
(Gollasch et al.’ 1992). Their inactivation is favoured by repolarization and 
hyperpolarization. During repolarization, the channels are inactivated but the 
inactivation is incomplete over a range of potentials. There is a range of membrane 
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potentials at which small but significant inward current is maintained. "Window 
current" is used to describe the voltage range at which this phenomenon occurs 
(Cohen et al., 1987; Negishi et al., 1995). On the other hand, the L-type Ca^^ 
channels can be closed by hyperpolarization triggered by Kca channels in response to 
raised [Ca:.]/. 
The L-type Ca^ "^  channels are made up of four pore-forming domains (a-subunits) 
each with six membrane-spanning segments (Si-Se) and some accessory subunits. 
The a-subunits confer the pore selectivity for Ca^ "^  ions and voltage sensitivity 
(Sanders, 2001). These channels are characteristically blocked by dihydropyridines 
such as nifedipine and nicardipine. The dihydropyridine ring of these molecules was 
found to dock inside the crevice formed between the tilted S6 helices of domains III 
and IV. The channel's inactivated state was thought to be stabilised by the non-polar 
interactions between the ester group on the port side of the dihydropyridine ring and 
the hydrophobic side chains on the bottom of the binding cavity (Lipkind et al., 
2003). — 
Activity of L-type Ca2+ channels can be modified by second messengers, such as 
diacylglycerol (DAG), a product of the phosphatidylinositol phosphate (PIP2) 
hydrolysis stimulated by Gq protein-coupled receptor activation. DAG activates 
PKC which has been shown to increase the open probability of L-type calcium 
channel on a skeletal muscle preparation from rabbit (Ma et al., 1992). It was later 
found that the enhanced open probability was mediated by phosphorylation of the cti-
subunit of the channel (Gutierrez et al., 1994). 
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Often, L-type calcium channels may not be activated directly by receptor activation 
or the second messengers but they may be regulated indirectly by the changes in 
membrane potential produced by these processes. Moreover, there are non-selective 
cation channels which can cause Ca^ "^  entry though the L-type calcium channels or 
other VDCCs by inducing depolarization. 
Some voltage-dependent calcium channels are not sensitive to dihydropyridines. 
For example, the transient or T-type calcium channels have been identified in 
vascular smooth muscle cells from several preparations including the rat aorta, rabbit 
ear artery and the guinea-pig coronary artery (Akaike et al” 1989; Benham et al,, 
1987; Ganitkevich et al,, 1990). However, their physiological role remains obscure. 
Recently, Morita et al. found a new type of nifedipine-insensitive calcium channels 
(NICCs) with high expression in the submucosal arterioles of the guinea-pig ileum 
and the terminal branches of mesenteric artery of guinea-pig and rat (Morita et al., 
1999; Morita et al., 2002). Judging from the activation threshold and the ionic 
peTmeability/blocking efficacy of divalent ions, the NICCs are belonged to the high 
voltage-activated VDCC type. However, they are resistant to nifedipine, verapamil, 
ditiazem and peptide blockers like co-agatoxin and co-conotoxins (Morita et al,, 1999). 
The NICCs are rapid inactivating and their inactivation is independent of calcium. 
The biophysical properties of the NICCs are distinct from the other known types of 
VDCCs, however, Morita and co-workers later found that they have very similar 
pharmacological profiles to the T-type calcium channels. The NICCs are blocked by 
agents that are normally used to block the T-type channels (Morita et al., 2002). 
Although the precise physiological role is yet to determine, the authors speculated 
that the NICCs might be crucial in controlling the vascular tone of small arterioles 
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since they are predominantly expressed in the periphery where the current density of 
L-type channels diminishes (Morita et al.’ 1999). 
The Ca2+ entry mechanisms discussed above are by no means comprehensive. In 
smooth muscles, there are also some agonist-activated and stretch-sensitive non-
selective cation channels. Ca^^ influx can also be triggered by depletion of internal 
Ca2+ store although the mechanism is still unclear (Sanders, 2001). 
1.2.1.2 Intracellular Ca^^ stores 
The sarcoplasmic reticulum (SR) is not an organelle that simply stores Ca^^, it also 
takes up excessive free Ca^^ and controls its release so as to maintain a low 
The release of Ca^ "^  from the SR is receptor-mediated. InsPa receptors frequently 
feature in G protein-coupled receptor-mediated vasoconstriction. Activation of Gq 
protein brings about the phospholipase C-catalysed hydrolysis of PIP2. InsPs is one 
of the products of hydrolysis and acts as a second messenger. It activates the InsPa 
receptors on the SR releasing Ca^ "^  to the cytoplasm. The increased free cytoplasmic 
Ca2+ then complexes with calmodulin and subsequently activates the contractile 
machinery of the cell. The activation of InsPs receptor is modulated by cytoplasmic _ 
Ca2+ in a biphasic manner (Bezprozvanny et al” 1991; lino, 1990). At low [Ca^^jz, 
InsPs is more effective in activating InsPa receptors and hence releasing Ca^^ when 
[Ca2+]/ is raised. However, high levels of (> 300 nM) reduce the open 
probability of InsPs receptors. It is essentially a negative feedback mechanism. 
The ryanodine receptor (RyR) is another type of Ca^^ channel on the SR membrane. 
It is activated by cytoplasmic Ca^ "^  and caffeine, and is blocked by ryanodine, a plant 
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alkaloid. Micromolar concentrations of cytoplasmic Ca^ "^  are required to initiate the 
Ca2+-induced Ca^^ release from the RyR channels (lino 1989) and therefore questions 
are raised on its physiologically relevance (Sanders, 2001). 
1.2.1.3 Ca2+ sparks and Ca^^ puffs 
When we talk about vascular smooth muscle contraction initiated by raising [Ca^" ]^/, 
we refer to the global However, sometimes release of Ca^ "^  from the 
intracellular store can be transient and highly localized, producing Ca^ "^  sparks or 
Ca2+ puffs depending on the receptor mediating the event. Ca^ "^  sparks result from 
localized Ca^ "" release from RyR (Nelson et al., 1995). It has been thought that Ca^^ 
sparks are produced by a cluster of RyRs close together rather than by a single RyR 
(Berridge, 1997). The release of Ca^ "^  through RyR can be triggered by Ca^ "^  influx 
or Ca2+ release from nearby InsPs receptors. The Ca^ "^  sparks could activate the Kca 
channels resulting in hyperpolarization and closure of VDCC if Kca channels and 
RyRs are in close proximity. 
The organization of the receptors on the SR is important for the Ca^ "^  sparks and 
RyRs to produee significant physiological effects. Gollasch and colleagues 
demonstrated that neonatal cerebral arterial cells possess functional RyRs that 
responded to caffeine activation but the Ca^^ sparks frequency was about 1% of adult 
cells. The authors found no significant difference in [Ca "^^ ]/, amplitude of Ca?. 
sparks, and density of RyR between the neonatal and adult arterial cells. A lack of 
coordinated opening of clustered RyR was put forward to explain the observation. 
The neonatal cells possess functional Kca channels and VDCCs. In the absence of 
Ca2+ sparks, the open probability of Kca was very low. Therefore, the feedback 
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mechanism (hyperpolarization) was uncoupled by the lack of Ca^ "^  sparks. The 
authors concluded that RyRs have to generate Ca^^ sparks to regulate arterial 
functions (Gollasch et al., 1998). 
On the other hand, if Ca^ "*" sparks happen to couple with Ca^"^-activated CI" channels, 
depolarization will occur. Therefore, this mechanism can be employed by different 
smooth muscles to generate diverse effects. 
Ca2+ puffs are similar localized Ca^^ transients mediated by InsPs receptors. That 
this process is mediated by G protein-coupled receptor is suggested. The incidence 
of Ca2+ puffs in colonic myocytes was found to be increased by the P2Y receptor 
agonist, 2-methylthio-ATP and this effect was blocked by U-73122, a PLC inhibitor. 
(Sanders, 2001). InsPs-mediated Ca^ "" puffs have also been shown to couple to both 
BKca and SKca channels, leading to hyperpolarization. It might account for the 
biphasic relationship between [Ca^ "^ ]/ and sensitivity of InsPs receptors to InsPs 
(Sanders, 2001). 
1.2.2 Ca2+sensitization -
1.2.2.1 Inhibition of myosin light chain (MLC) phosphatase 
Ca2+ sensitization refers to the mechanisms through which agonists induce contractile 
force at a given level of [Ca "^^ ]/. This concept has been proposed for more than three 
decades (Somlyo et al., 1968). It was proposed that G protein-coupled receptor 
agonists increased Ca^ "^  sensitivity by inhibiting a myosin phosphatase (Somlyo et al., 
41 
Chapter 1 - Introduction 
1989). However, the mechanisms have only been intensely revealed over the last 
decade. 
Study with permeabilized rabbit portal vein showed that, apart from releasing 
intracellular Ca^ "^  by InsPs, phenylephrine and GTPyS also raised the contractile 
response of guinea-pig portal vein to buffered cytoplasmic Ca^ "^  (Kitazawa et al,, 
1989). In the rabbit portal vein, the Ca^ "^  sensitizing effect of GTPyS was caused by 
inhibition of MLC dephosphorylation without affecting activity of MLC kinase 
(Kitazawa et al.’ 1991). This experimental evidence matched up with the previous 
hypothesis that Ca^ "*" sensitization of smooth muscle caused by the inhibition of MLC 
phosphatase via a G-protein coupled mechanism (Somlyo et al., 1989). 
1.2.2.2 Activation ofRhoA 
RhoA is a low molecular weight monomelic G protein belonged to the Rho 
subfamily. In the early 1990，s，the Rho subfamily was identified to be involved in 
the Ca2+ sensitization pathway. EDIN and C3 are bacterial exoenzymes that ADP-
ribosylate Asn 41 of RhoA. They were shown to inhibit the GTPyS-enhanced Ca^^ 
sensitivity in skinned rabbit mesenteric artery (Hirata et al., 1992)._ It was later 
demonstrated in permeabilized porcine aortic smooth muscle cells that GTPyS-
induced Ca^ "*" sensitization was mediated through the inhibition of the— 
dephosphorylation but not the activation of thiophosphorylation of myosin light 
chain. The Ca^ "^  sensitization effect of GTPyS was abolished by pre-treatment with 
C3 (Noda et al., 1995). Taken together, Rho is evidently involved in agonist-induced 
MLC phosphorylation and subsequent contraction of vascular smooth muscle 
without increasing [Ca^^Jz. 
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Like the heteromeric G proteins, RhoA is inactive when bound to GDP and becomes 
active when bound to GTP. Unlike the heteromeric G proteins, the exchange of GDP 
for GTP on RhoA is not coupled to a receptor but is catalyzed by the guanine 
nucleotide exchange factors (GEFs). The activation of RhoA is also modulated by 
GTPase activating proteins (GAPs) and guanine nucleotide dissociation inhibitors 
(GDIs). GAPs inactivate RhoA by accelerating its intrinsic GTPase activity whereas 
GDIs bind to small G protein and keep it in the cytoplasm (Sah et al, 2000). 
The localization of RhoA is important for its activity. RhoA-GDI complex in the 
cytoplasm is activated by GEFs. The complex is then dissociated. The activated 
RhoA (GTP-bound) is translocated to the plasma membrane whereas GDI remains in 
the cytoplasm. Gong and co-workers demonstrated a causal role of RhoA 
recruitment induced by phenylephrine and GTPyS, to the plasma membrane in Ca^ "^  
sensitization by assessing the particulate hydrophobic fraction of the G protein (Gong 
et al” 1997). RhoA is a hydrophobic protein due to its prenylated carboxyl terminus 
which associates with the plasma membrane when activated or with the hydrophobic 
pocket of GDI in the cytoplasm (Somlyo et al., 1999). 
1.2.2.3 Rho-kinase 
The activ^ed RhoA is localized in and its effect is dependent on a relatively intact 
plasma membrane. How does it communicate with MLC in the cytoplasm and cause 
its phosphorylation? Leung and co-workers isolated and characterised a RhoA-
binding protein that possess an amino-terminal serine/threonine kinase domain from 
a rat cDNA (Leung et al., 1995). The kinase was then demonstrated to 
phosphorylate myosin-binding subunit of myosin phosphatase, which was associated 
43 
Chapter 1 - Introduction 
with a decrease in MLC phosphatase activity (Kimura et al., 1996). This Rho-
associated kinase (Rho-kinase) was also shown to phosphorylate MLC 
stoichiometrically at Ser 19，the same binding site of MLC kinase in a cell-free 
system (Amano et al., 1996). However, this direct phosphorylation of MLC was 
found to be unimportant in Rho-mediated smooth muscle contraction. In 
permeabilized rabbit tracheal smooth muscle, it was demonstrated that MLC kinase 
activity and the presence of Ca^ "^  were required for GTPyS-induced contractile force 
in [Ca^"^]/-buffered solution (lizuka et al., 1999). In permeabilized guinea-pig ileum, 
at low [Ca2+]/ of pCa 9’ Rho-kinase induced force primarily through phosphorylation 
of MLC phophatase but not via direct phosphorylation of MLC (Sward et al, 2000). 
Additional observations have further supported Rho-kinase as a key component in 
the G protein-mediated Ca^ "^  sensitization pathway. It was found that contractile 
effect upon G protein activation was lost in extensively permeabilized smooth 
muscle with Triton X-100 (Gong et al., 1996). It was later speculated to be due to 
the loss of Rho-kinase since Rho-kinase and other cytosolic proteins were found to 
be missing in extensively permeabilized cell (Kureishi et al., 1997). The authors also 
reported that a constitutively active form of Rho-kinase induced contraction o f -
permeabilized rabbit portal vein in both the presence and the absence of cytosolic 
Ca2+ in a wortmannin-insensitive and hence Ca^^-CaM-independent manner. 
The experimental evidence described above strongly indicates that Rho-kinase is a 
crucial effector in conveying the signal input from RhoA to the contractile apparatus 
independent of Ca^ "^  mobilization. This theory is further supported by the use of 
specific inhibitor of Rho-kinase. Y-27632 is by far the most frequently used Rho-
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kinase inhibitor. It has K\ values of 0.14, 25, 26 and >250 |aM for Rho-kinase, PKA, 
PKC and MLC kinase respectively. As an anecdotal observation, since Y-27632 was 
identified to specifically inhibit Rho-kinase, the report by Uehata et al. in October, 
1997 has been cited in at least 552 articles in scientific journals^ 
HA-1077 (fasudil hydrochloride) is now used less in the laboratory for inhibition of 
Rho-kinase since it is less selective than Y-27632, inhibiting several other protein 
kinases (Davies et aL, 2000; Uehata et al., 1997). Recently, HA-1077 has been 
modified to yield a more selective Rho-kinase inhibitor, H-1152 (Sasaki et al” 2002). 
H-1152 is a potent Rho-kinase inhibitor with a K\ value of 1.6 nM. Its potency for 
PKA inhibition was found to be about 400-fold lower (Sasaki et al., 2002). 
Apart from being useful biochemical and pharmacological tools in laboratory, Rho-
kinase inhibitors are potentially therapeutic agents for the cardiovascular system. 
Both HA-1077 and Y-27632 have been studied for cerebral vasospasm after 
subarachnoid haemorrhage. HA-1077 in fact was taken to the clinic for a 
prospective randomized placebo-controlled, double-blind trial (Shibuya et al” 1992). 
Recently,-Sato and co-workers showed that topical application of Y-27632 to the 
canine basilar artery exposed transclivally reduced the intensities of vasospasm and 
phosphorylation of myosin-binding subunit 些d MLC. The cerebral vasospasm was 
produced by a 2-haemorrhage method which mimicked subarachnoid haemorrhage 
(Sato et al, 2000). In addition, Y-27632 was found to correct hypertension in 
spontaneous hypertensive, renal hypertensive and deoxycorticosterone acetate-salt 
‘Figure obtained on 16& June, 2003 from http://isi5.isiknowledge.com/ (ISI Web of Science). 
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hypertensive rats but it did not produce significant effect in the control rats (Uehata 
et al., 1997). 
1.2.2.4 Regulation by G proteins 
Most of the evidence presented points to the G12/13 protein family being the upstream 
mediator of the Rho/Rho-kinase pathway. Although many of the G protein-coupled 
receptor agonists that cause Ca sensitization via the Rho/Rho-kinase pathway are 
coupled to Gq protein, collective evidence, mainly from the Rho-dependent 
cytoskeletal responses studies suggests that Gq-mediated pathways are not sufficient 
to regulate the Rho/Rho-kinase pathway (Sah et al., 2000). TP receptor-mediated 
shape change of platelets is one of the examples to demonstrate the role of the two G 
protein-mediated pathways in the Rho/Rho-kinase system. Klages and co-workers, 
using Gaq-deficient mice, showed that U-46619-induced platelet aggregation and 
degranulation but not shape change were dependent on the Gq pathway (Klages et al., 
1999). Platelet shape change involves reorganization of the cytoskeleton which is 
dependent on MLC phosphorylation (Daniel et al, 1984; Nachmias et al, 1985). Y-
27632 and C3 were found to inhibit the U-46619-induced MLC phosphorylation in 
the Gaq-deficient platelets (Klages et al., 1999). In these Gaq-deficient platelets, G^ 
and Gi3 were the only G proteins that coupled to the TP receptors. Therefore, it was 
concluded that the MLC phosphorylation in the platelets is signalled through the 
Rho/Rho-kinase pathway mediated by G12 and G13 proteins. 
The Rho-mediated effects are largely activated by G proteins that are pertussis toxin-
insensitive, however, some have reported the involvement of Gj/o-mediated systems. 
For example, Betuing and co-workers demonstrated that ot2-mediated actin 
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cytoskeletal rearrangement in preadipocytes was pertussis toxin-sensitive and was 
controlled by the Rho-mediated system since C3 exoenzyme inhibited such effect 
(Betuing et al., 1998). 
1.2.2.5 Role of PKC 
Many agonists that are capable in enhancing Ca^ "^  sensitivity in smooth muscle cells 
are coupled to PIP2 hydrolysis via Gq protein. PKC, stimulated by DAG was shown 
to elicit smooth muscle contractions at constant [Ca^ "^ ]/ in studies using phobol esters 
(Jiang & Morgan，1987; Lee & Severson, 1994; Singer & Baker，1987) and thought 
2+ • • • 
to play an important role in Ca sensitization. However, recent studies dismiss the 
idea that conventional or novel PKC plays an essential role in G protein-coupled 
Ca2+ sensitization. Agonist- and GTPyS-induced Ca^ "^  sensitization were not affected 
by down-regulation of PKC in several smooth muscle preparations (Jensen et al., 
1996). Walker and co-workers demonstrated that phobol ester-induced Ca^^ 
sensitization was due to MLC phosphorylation but PKC-s was not necessary for the 
process (Walker et al., 1998). . 
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1.3 Aim of study 
My task was to investigate the mechanism underlying the synergism between an EP3 
agonist and other contractile agents on vascular smooth muscle. It had been reported 
that sulprostone and phenylephrine showed moderate synergism on guinea-pig aorta 
(Shum et al., 2003). My first experiment, using rat femoral artery showed that the 
direct contractile action of sulprostone was weak, but the synergism was very marked. 
This appeared to be a system worthy of further study. Three major aspects of the 
synergism were investigated: (a) the nature of the prostanoid receptor involved, (b) 
the role of L-type Ca^^ channels, and (c) the role of Rho-kinase. 
In addition, I wished to know whether EPs-mediated vasoconstriction could be 
demonstrated on an arterial bed in vivo. Since the technique of laser Doppler 
perfusion imaging of the rat knee joint vasculature was being used in the Department 
of Pharmacology, I decided to leam the technique and study the action of sulprostone. 
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Chapter 2 Methods and Materials 
Most of the experiments were to investigate the characteristics of the EP3 receptor on 
the rat femoral artery using a small vessel myograph. A few experiments were 
performed on the guinea-pig trachea in conventional organ baths to evaluate SC-
51322, an EPi antagonist. 
2.1 Experiments with rat femoral artery 
2.1.1 Animals 
Male Spraque Dawley rats, weighing 250 - 300 g were killed by cervical dislocation 
and exsanguination. All the animals were supplied by the Laboratory Animal 
Services Centre of the Chinese University of Hong Kong. 
2.1.2 丨solated tissue preparations 
The femoral artery, approximately 1.5 cm in length, was excised from the-rat and 
then kept in Krebs-Henseleit solution (see section 2.3.1 for composition) containing 
indomethacin, 1 The adherent fat and connective tissue were removed under a 
microscope using fine forceps. The segment was cut into four rings, about 2 mm in 
width, and each was mounted in a small vessel myograph. 
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2.1.3 Small vessel myograph 
A Multi Myograph System - model 610M (Danish Myo Technology A/S) was used 
to measure isometric tension of the vessel rings. The design of one of the four 
stainless steel (10 ml) chambers is shown in Figure 2.1. One of the jaws is attached 
directly to the force transducer and the other to a micrometer screw that alters the 
distance between the jaws. Outlets for aeration and solution exhaustion are situated 
at one side of each chamber. The solution in the chamber is exhausted to a flask 
connected to a vacuum pump. To reduce evaporation and maintain oxygen tension, 
each chamber has a plastic cover. There are separate ports in the plastic cover to 
allow the addition of drug and solutions for washing. The temperature of the 
solution in the myograph was held constant at 37°C. 
2.1.4 Data acquisition 
The myograph system was connected to a PowerLab recording unit linked to an iMac 
• computer. The data were recorded using Chart 3.6 / 4.01 (Macintosh) software and 
the sampling rate was 40 Hz. 
2.1.5 Calibration of the myograph 
A calibration kit including a bridge, a balance and a 2-g weight was supplied with the 
myograph. For each chamber, a stainless steel wire (diameter 40 )im) was mounted 
to the jaw attached to the transducer side. Then, the calibration bridge and balance 
were placed on the chamber as described in the User Manual. However, the 
"calibration menu" on the interface of the myograph was not utilised. Instead, the 
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software Chart was used to calibrate the input data from the myograph with a two-
point calibration: 0 and 2 g. 
2.1.6 Mounting of the ring preparations 
The chambers were filled with bathing solution (see section 2.3.1 for composition) 
and the built-in heater was turned on to keep the solution at 37°C. Each vessel ring 
was positioned at the centre of the chamber by attaching the stainless-steel mounting 
wires (40 |_im diameter) to the jaws (see Figure 2.1). First, a wire about 2.5 cm long 
was fed through the lumen of the vessel. Then, one end of the wire was wrapped 
clockwise under the screws of the stationary jaw with a pair of forceps. The screw 
was tightened with a small screwdriver. This step was repeated for the other end of 
the wire. Then, another wire was fed through the vessel and secured to the adjustable 
- jaw similarly. The jaws were kept close to each other to prevent stretching of the 
vessel. The plastic covers were placed on the top of the chambers and through the 
ports on the covers, the suction pipes were inserted into the chambers. The "zero 
menu" on the interface was used to zero the output of the transducers before applying 
any force on the vessels. 
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(a) 
/ Stainless steel wire 
/ j Vessel ring 
Transducer • — — - • 
(b) 
Can be rotated 
and inserted into 
the bath 
Gas from carbogen cylinder ( ^  
^ ^ 二 Exhaust pipe connected to vacuum pump 
ff z — — 
Organ bath chamber 
Figure 2.1 (a) Bird's-eye view of a chamber of the myograph, (b) View of a 
chamber from the side. 
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2.1.7 Experimental procedure 
The common protocol applied to all the experiments (unless stated otherwise) is 
given below. An initial tension of 1.10 to 1.20 g was applied to the tissue, followed 
by a rest period of about one hour. During the resting period, the tissue was 
stretched to achieve the target basal tension of around 1 g. A stable tension was 
attained before any drug was added to the bath. 
After the equilibration period, the preparations were first challenged with a dose of 
40 mM KCl. ACh, 3 |_iM was added to check the presence of functional endothelium. 
The preparation was then washed and challenged again with 40 mM KCl to test the 
reproducibility of the contraction. L-NAME, 100 |iM was added 10 minutes before 
the second KCl dose if the preparation showed endothelium function in the previous 
challenge. ACh, 3 was used again to assess the extent of NO involvement in the 
endothelial relaxation. Preparations showing responses to 40 mM KCl of less than 
0.5 g were discarded. 
The preparations were then washed and a steady baseline of about 1 g was achieved 
before the main investigation was started. L-NAME, 100 was present in 
-p repara t ions with functional endothelium. GR-32191, 1 |iM, a TP receptor 
antagonist, was added to preparations on which sulprostone, SC-46275 and 17-
phenyl-PGE2 were to be used. Both agents were introduced 10 minutes before the 
first dose was added. 
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The main investigations included (1) the concentration-dependent effects of EP3 
agonists; (2) their interactions with other vasoactive agents, mainly KCl and 
phenylephrine and (3) the effects of various blockers and inhibitors on these 
contractile effects. Figure 2.2 shows a schematic representation of the main 
protocols. 
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(1) 
Agonist (cumulative doses) 
Tension 广 
(2) 
Agonist (cumulative doses) 
丰 ^ Tension Pre-contractant + ^  ‘ 
(3) — 
Agonist (cumulative doses) 
• ‘ i 
Tension Pre-contractant ’ 
-
Inhibitor / blocker 
Fig. 2.2 Schematic representation of the main protocols. (1) The concentration-
response curves of agonists were constructed cumulatively. (2) Cumulatively doses 
of agonist were added after a steady contraction by a single dose of contractile agent 
had been obtained. (3) The calcium channel blocker, nifedipine and several Rho-
kinase inhibitors were the main inhibitory compounds used in the project. 
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2.2 Experiments with guinea-pig trachea 
2.2.1 Animals 
Female Dunkin-Hartley guinea-pigs, weighing 400 - 500 g were sacrificed by 
cervical dislocation and exsanguinations. The animals were supplied by the 
Laboratory Animal Services Centre of the Chinese University of Hong Kong. 
2.2.2 Isolated tissue preparations 
The trachea, from the larynx to the head of the sternum, was excised from the 
guinea-pig and was transferred to a Petri dish filled with Krebs-Henseleit solution 
containing 1 )iM indomethacin. The adherent fat and connective tissue were cleared. 
Blood vessels_were removed as far as possible. The segment was cut into four rings, 
each approximately 3mm in width. Cuts were made between the cartilage rings. 
Two z-hooks with cotton threads attached were positioned in each ring, so that they 
sat on the cartilage not the smooth muscle band. 
2.2.3 Organ bath 
The trachea rings were then suspended in 10 ml organ baths containing Krebs-
Henseleit solution with 1 |iM indomethacin, aerated with carbogen (95% 02/5% 
CO2). The solution was kept at 37°C by the heated water jacket. The lower thread 
was fixed at the base of the organ bath while the upper thread was attached to the 
isometric force transducer (Grass FT03). The transducer was connected to a 
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MacLab/4 recording unit which was linked to a PowerMac computer system. The 
data were recorded using Chart 4.0 (Macintosh). 
2.2.4 Experimental procedure 
After mounting in the organ baths, the preparation was allowed to equilibrate for 
about one hour. The target basal tension was about 1.0 g. A stable resting tension 
was attained before any drug was added to the bath. The preparation was challenged 
twice with 10 j^ M ACh, to test the reproducibility of the contractions. GR-32191, 
200 nM was added before the subsequent tests with 17-phenyl-PGE2. 
Apart from the EP! activity, the guinea-pig trachea is also contracted by TP agonist 
and relaxed by EP2 agonists. 17-Phenyl-PGE2 is used as the standard EP! agonist on 
this preparation since it has very low TP and EP2 agonist potency (Lawrence et al., ‘ 
1992). Figure 2.3 shows the protocol. A dose-response curve for 17-phenyl-PGE2 
was first obtained during the first sequence. After washing, SC-51322 (10 and 100 
nM) or an equivalent volume of ethanol, the solvent, were added, followed 30 
minutes later by further cumulative doses of IT-phenyl-PGEz. Pilot experiments 
showed that 30 minutes were sufficient for the effect of SC-51322 to reach 
equilibrium. 
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wash 
17-Phenyl-PGE2 (cumulative doses) 
• 
Tension^ ‘ ^ ^ 广 
Second sequence 
17-Phenyl-PGE2 (cumulative 
Tension + ‘ 
SC-51322 
or 
17-Phenyl-PGE2 (cumulative doses) 
• 丰 - I ^ 
Tension + ^ ^ ‘ 
— Ethanol 
Figure 2.3 Schematic representation of the protocol. 
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2.3 Materials 
2.3.1 Physiological salt solution 
Krebs Henseleit Solution was prepared freshly before each experiment. The solution 
was composed of the following: 








The ingredients were dissolved in distilled water. Indomethacin was added to the-
solution to make a final concentration of 1 |iM. Indomethacin served as a COX 
inhibitor to prevent the production of endogenous prostanoids. _ 
2.3.2 Chemicals used 
Table 2.1 shows the chemical used in the project. The vehicle for all the serial 
dilutions of the stock was normal saline (0.9% NaCl w/v) unless stated otherwise. 
All the reconstituted solutions were stored at -20°C, except KCl solution which was 
kept at room temperature. 
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Table 2.1 Chemicals used in the myograph experiments. 
Drug Description M.W. St^k Source vehicle  Acetylcholine Endogenous ligand for 181.66 Distilled Sigma 
(ACh) muscarinic receptor water 
AFP-07 Selective LP receptor Distilled~~Asashi Glass Co., 
agonist water Japan  
BW245C Selective DP receptor 368.5 Wellcome 
agonist  
Cicaprost Selective IP receptor 374 Aqueous Schering 
agonist fluid  
Fluprostenol Selective FP receptor 458.5 Ethanol Sigma 
agonist  
GR-32191 Specific TP antagonist 357.8 Ethanol Glaxo, U.K. 
H-1152 Rho-kinase inhibitor Distilled Kitasato 
water University (Japan) 
Indomethacin Non-selective COX 357.8 Ethanol Sigma 
inhibitor 
• •‘ 丨—_ • • I •一 ••圓 I "“ •• ‘ • '• 
Nifedipine L-type Ca channel 346.34 Ethanol Sigma 
blocker  
Nco-Nitro-L- Competitive inhibitor of 269.7 Distilled Sigma 
arginine methyl nitric oxide synthase water 
ester (HCl) 
(L-NAME) — 
PGE2 Endogenous ligand for 352.55 Distilled Sapphrine 
EP receptors water  
L-Phenylephrine ai-Adrenoceptor agonist 203.67 Ethanol Sigma 
(HCl) — . 
17-phenyl-co-trinor EP1/EP3 receptor agonist 386 Ethanol Cayman 
PGE2  
Potassium chloride Depolariser of cell 74.56 Distilled Merck 
(KCl) surface membrane water  
- Ro 32-0432 Selective cell-permeable 489 DMSO Sigma ‘ 
- PKC inhibitor  
SC-46275 Selective EP3 receptor 418 Ethanol GD Searle，USA 
agonist  
SC-51322 Specific EP2 receptor Ethanol ^ Biomol 
antagonist  
Sulprostone EP3/EP1 receptor agonist 465.5 Ethanol Schering  
U-46619 Selective TP receptor 350.5 Ethanol Sigma “ 
agonist  
Y-27632 Rho-kinase inhibitor 3 3 8 . 3 D i s t i l l e d W e l f i d e (Japan) 
water * 
*Distilled water was used for further dilutions. 
#Ethanol was used for further dilutions. 
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2.4 Data analysis 
Unless stated otherwise, responses were expressed as the change of absolute tension 
in grams induced by the compounds used. Values are presented as mean 土 SEM. 
The GraphPad Prism program (GraphPad Software Inc.) was used to plot and analyse 
sigmoidal log concentration-response curves. 
Analysis of variance (ANOVA) accompanied by comparison of means by pre-
planned contrasts was performed with SuperANOVA software (Abacus Concepts 
Inc.). Repeated-measures two-factor ANOVA model was used to analyse the 
significance of main effects and the difference between factor levels (Glass et al, 
1995). The repeated-measures (within-subject) factor was the dose effect in a given 
preparation and the between-subject factor was the main effect of treatment on 
matched preparation. Pre-planned contrast was used to compare the difference 
between mean values of two curves. 
Student's t-tests (paired and unpaired), which were used to compare parameters, for 
example IC50 values, of two groups were performed with the GraphPad Prism 
program. One-factor ANOVA with post hoc Bonferroni's multiple comparison test 
was carried out to compare parameters of three groups. All the statistical analyses 
presented in this thesis are two-tailed. Difference with P value less than 0.05 is taken 
as statistically significant, "n" is the number of animals used. 
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2.5 Measurement of rat knee joint blood flow 
Laser Doppler perfusion imaging technique was employed to assess the effect of 
sulprostone in vivo by measuring relative change in blood flow of rat knee joint. 
2.5.1 Animals 
Male Spraque Dawley rats, weighing 250 - 300 g were used in this study. All the 
animals were supplied by the Laboratory Animal Services Centre of the Chinese 
University of Hong Kong. 
2.5.2 Anaesthesia of animals 
The rats were anaesthetised with 1.8 g/kg of urethane (25% w/v) given by . 
intraperitoneal injection. An additional 0.2 ml (0.05 g urethane) of the anaesthetic 
was administered when the animal showed-signs of consciousness or muscle reflex 
when operated on. When required, this step was repeated 10 minutes after the last 
injection. The range of urethane (25% w/v) given to individual animals used in these 
experiments was 1.8 - 2.4 ml. 
2.5.3 Preparatory surgery 
2.5.3.1 Cannulation of rat trachea 
Stable anaesthesia was normally achieved in about 10 minutes. The animal was 
placed in dorsal recumbency on a dissecting tray. The trachea was exposed after 
being cut open the skin of the larynx region and the longitudinal muscle underneath. 
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The trachea was freed from connective tissues before a small cut was made between 
two cartilage rings of the trachea. A cannula was then inserted into the opening and 
secured with cotton thread. Care was taken not to introduce any fluid or blood into 
the trachea. 
2.5.3.2 Cannulation of carotid artery 
The carotid artery was cannulated for blood pressure monitoring. The right carotid 
artery was located and freed from connective tissues. A bulldog clip and cotton 
thread were used to restrict the blood flow to and from the site of cannulation so as to 
stop the loss of blood once a cut was made for the cannulation. Between these two 
points, a slanted cut was made. A cannula connected to a three-way tap and a 1ml-
syringe filled with heparinised saline was inserted into the artery and secured with 
cotton threads. The tap was closed at the cannula side. 
2.5.3.3 Blood pressure measurement 
In the time course experiments, systemic blood pressure was monitored to check that 
any local change in knee joint blood flow did not result from a change in systemic 
blood pressure. A pressure transducer was attached to the free way of the three-way 
tap connected to the cannula. The transducer was linked to a PowerLab amplifier 
_ that was connected to the recording software, Chart (PC). 
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2.5.4 Measurement of joint blood flow 
2.5.4.1 Preparing for blood flow measurement 
Skin over the medial aspect of the rat knee joint was excised, and the membrane 
immediately underneath was also removed. A piece of cotton wool was used to 
surround the exposed knee joint. Normal saline (NaCl 0.9%w/v) was added to keep 
the exposed surface and the cotton wool hydrated. The feet and body of the rat was 
restrained using adhesive tape. 
2.5.4.2 Settings of the LDI measurement 
Relative changes of the joint blood flow were measured by a laser Doppler perfusion 
imager (LDI) (Moor Instruments, Axminster, UK) placed 28 cm above the joint. The 
imager directed a laser of dual wavelengths (helium-neon) to the tissue. An area of 
7.5 cm X 7.5 cm covering two knee joints was scanned in approximately 45 s. The 
imager was connected to a computer that displayed a colour-coded perfusion image 
for each scan. The colours represented different degree of flux at each point of the 
image. 
2.5.5 Experimental protocol 
2.5.5.1 Time course experiments -
Time course experiments were performed with two doses of sulprostone, 10"^  and 
10-8 moi. A pair of rats was used in each experiments and only one knee joint of 
each animal was studied each time. Initially, the exposed knee joints were washed 
with normal saline and scanned every 5 min. Once the blood flow had stabilised, 
three baseline readings were taken. Each reading was taken 5 min apart and 100 j^ iL 
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of normal saline was added to each knee joint immediately before the start of 
scanning. After the baseline measurements, 10'^  mol of sulprostone (100 jiL x 10 
I^M) was applied to each knee joint and scans were performed at 0, 1, 2, 5, 10 and 
every 5 min thereafter. The last scan was taken at 60 min after dosing. 
After the experiment, the knee joints were washed with normal saline and covered 
with cotton wool. The other knee joint of each animal was then exposed according 
to the steps described in section 2.5.4.1 and the above procedures were repeated. 
The same protocol was followed for 10"^  sulprostone (100 \xLx 100 ^iM). 
Since ethanol was the vehicle of the stock solution of sulprostone, similar procedure 
was carried out to investigate the effect of ethanol on the rat knee joint blood flow. 
After the baseline measurements, 100|_iL of ethanol (0.1%) was applied to two knee 
joints. Scans were performed at 0，1，2，5, 10 and 15 min as the effects of 
sulprostone were observed during the first 15 min. After 15 min, the knee joints 
were washed with normal saline for 15 min. Then the same procedure was repeated 
for 1% ethanol. For the other two knee joints, the reversed order of ethanol 
coneentrations (i.e. 1% and then 0.1%) were tested with the same protocol. Ethanol 
1% and 0.1% are the corresponding concentrations of ethanol in 100 and 10 j_iM 
sulprostone solutions respectively. 
2.5.5.2 Dose-response experiments 
The above time course experiments revealed a tendency for sulprostone to induce 
elevation in flux. Therefore, the effect of sulprostone was investigated with more 
extensive range of concentrations. For each dose, scan was performed at 0, 1, 2，5， 
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10 and 15 min after the addition of drug. Then the knee joints were washed and a 
baseline measurement was taken before repeating the procedure with the next dose. 
19 o 
The doses ranged from 10" to 10" mol were tested in ascending order. The effects 
of the corresponding ethanol concentrations were investigated using the same 
protocol. 
2.5.6 Chemicals used 
Table 2.2 shows the chemicals used in the LDI experiments. NaCl 0.9% w/v was 
used for further dilutions of sulprostone. 
Table 2.2 Chemicals used in the LDI experiments. 
Drug Description M.W. Stock vehicle Source 
-Su lp ros tone EP3/EP1 receptor agonist 465.5 Ethanol Schering 
Urethane (Ethyl Anaesthetic 89.09 NaCl 0.9%w/v Sigma 
carbamate)  
2.5.7 Data analysis 
GraphPad Prism program (GraphPad Software Inc.) was used to plot the graphs. All — 
the values presented are the effect of sulprostone less the effect of the corresponding 
concentration of ethanol, the vehicle of sulprostone solution. Results are expressed 
as mean 士 SEM. Analysis of variance (ANOVA) with pre-planned contrasts was 
performed with SuperANOVA software (Abacus Concepts Inc). For the time course 
experiments, repeated-measures two-factor ANOVA model was used to analyse the 
time course profiles between different doses of sulprostone. For the dose-response 
experiments, one-factor ANOVA with post hoc Bonferroni's multiple comparison 
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test was performed to compare the effect of each dose with the baseline. All 
statistical analyses are two-tailed. A difference with P value less than 0.05 is taken 
as statistically significant, "n" is the number of knee joints examined. 
67 
Chapter 3 - Results 
Chapter 3 Results 
3.1 Effects of EP3 agonists and other vasoactive agents on the rat 
femoral artery preparation 
Figure 3.1 shows concentration-response curves for the EP3 agonist sulprostone and 
some common vasoactive agents on rat femoral artery (RFA). U-46619 was the 
most potent contractile agent with EC50 values of 11.2 nM and a mean maximum 
contraction of 1.82 g. Phenylephrine was less potent (EC50 = 107 nM), while KCl 
only produced contractions above 10 mM (EC50 = 26 mM). Sulprostone, although 
quite potent (threshold effect = 0.4 nM), was a weak contractile agent. At 444.4 nM 
(cumulative concentration), it contracted the vessel with force reaching 16% of the 
U-46619 maximum. 
The natural agonist PGE2 induced contraction of the RFA as shown in Figure 3.2. 
Since PGE2 has activity at all the EP receptor subtypes, including EP2 and EP4 
receptors which mediate relaxation, it was decided to focus on the actions of more 
selective EP3 agonists. The responses of RFA to the PGE analogues, SC-46275, _ 
sulprostone and 17-phenyl-PGE2 are shown in Figure 3.3. The ranking of potency is 
SC-46275 > sulprostone > 17-phenyl-PGE2, which corresponds to EP3 as opposed to 
EPi agonism. 17-Phenyl-PGE2 at 100 nM induced 0.103 g of contraction, which 
corresponded to 3.5 and 8.9 nM of SC-46275 and sulprostone respectively, giving 
approximate equi-effective molar ratios of SC-46275 = 1.0，sulprostone = 2.5, and 
17-phenyl-PGE2 = 29. The potency of PGE2 is probably between those of 
sulprostone and 17-phenyl-PGE2. 
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3.2 Interactions between EP3 agonists and other vasoactive agents 
3.2.1 丨nteractions with phenylephrine 
Sulprostone induced contractions of RFA were enhanced by pre-contracting the 
preparation with a low dose of phenylephrine (Figure 3.5a). Figure 3.4 shows an 
experimental record of the synergism. In each experiment, hypothetical additive 
responses were obtained by adding the 100 nM phenylephrine-induced contraction to 
the corresponding sulprostone alone-induced contractions obtained on a preparation 
from the same animal, and a sigmoid curve was fitted to the mean responses. The 
effect of sulprostone (0.1 to 144.4 nM) was dramatically enhanced by pre-contracting 
the preparation with 100 nM phenylephrine. At each sulprostone concentration, the 
difference between addition and pre-contracted means was significantly different 
(repeated measures two-factor ANOVA with _ pre-planned contrasts) (RM-2F-
ANOVA/PPC). 
Similar synergism was observed for SC-46275 with 100 nM phenylephrine (Figure 
3.5b). It is noteworthy that lowest concentration (0.1 nM) of sulprostone and SC-
46275 did not produce overt contraction of RFA but induced significant contraction 
on pre-contracted preparation. On the other hand, statistical significance was not 
— detected {P = 0.15) for the main-effect between the pre-contracted and the additive 
curves of 17-phenyl-PGE2 (Figure 3.3c). However, the enhancement of the last three 
responses of 17-phenyl-PGE2 (14.4 - 144.4 nM) was significant. It was interesting to 
note that, although statistical significance was not reached, concentrations of 17-
phenyl-PGEz 0.1 and 0.4 nM gave small contraction that faded to below the 
phenylephrine response. Figure 3.6 shows a tracing for this effect. 
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The phenylephrine/sulprostone interaction was further investigated using different 
levels of pre-contraction. Synergism with sulprostone was observed for 30，100 and 
300 nM phenylephrine-induced contraction. Figures 3.7a to c show results for one 
pre-contraction dose only, including the corresponding additive curve. A tendency 
for increased sensitivity to sulprostone as the pre-contraction level increased was 
observed; EC50 values for the combined phenylephrine/sulprostone curves were 2.8, 
0.92 and 0.3 nM respectively (Figure 3.8). On the other hand, although the 
phenylephrine (30 nM)/sulprostone curve seemed to have a lower maximum than the 
other two pre-contracted curves, the differences between the maximum asymptotes 
of the three pre-contracted curves were not statistically significant, perhaps 
indicating that these combinations were approaching the same level of contraction. 
Increasing the dose of phenylephrine or sulprostone might not increase the tension 
any further. 
Figure 3.9 shows how varying phenylephrine concentration affects the contractions 
produced by subsequent addition of 17-phenyl-PGE2. With 30 and 100 nM — 
phenylephrine, synergistic interaction was observed for 17-phenyl-PGE2 at and 
above 14.4 nM. Significant differences were detected between the addition and pre-
contracted means in the last three responses of 17-phenyl-PGE2 (14.4，44.4 and 144.4 
nM) (additive curve not shown). However, with 300 nM phenylephrine there was 
much greater variation and the data would not be fitted to a sigmoidal curve. 
An observed/additive ratio was devised to give a potency estimate of the agonist 
synergy caused by the EP3 receptor agonists used. Contractions induced by 100 nM 
phenylephrine in combination with sulprostone, SC-46275, 17-phenyl-PGE2 or 
70 
Chapter 3 - Results 
fluprostenol were divided by the corresponding hypothetical additive value. The 
additive value is the sum of the contractions produced by 100 nM phenylephrine and 
the corresponding response to the EP3 agonist alone. From Figure 3.10, we can see 
that sulprostone and SC-46275 developed stronger synergism with phenylephrine 
than 17-phenyl-PGE2 and fluprostenol (discussed later). The observed/additive ratio 
was set at 2.5 in order to compare the potencies of sulprostone, SC-46275, 17-
phenyl-PGE2 and fluprostenol. The corresponding agonist concentrations are 0.16, 
0.4，31.6 and 2000 nM respectively, giving approximate equi-effective molar ratios 
of 1.0，2.5, 200 and 12,500 respectively. 
3.2.2 Interactions with KCI 
EP3 agonists interacted with KCI similarly to phenylephrine. Figure 3.11 is an 
experimental record of PGE2-induced contraction on a vessel pre-exposed to KCI. 
Figures 3.12a to c show that 20 mM KCI potentiates the responses of the preparation 
to sulprostone； SC-46275 and 17-phenyl-PGE2. For sulprostone and SC-46275, the 
synergism was statistically significant over the entire range of concentrations tested, 
— whereas for IT-phenyl-PGEi the synergism was significant above 3.4 nM. The 
tendency for lower concentrations of 17-phenyl-PGE2 to relax the pre-contracted 
tone seen with phenylephrine was not observed in this set of experiments. 
The effect of varying pre-contraction level by using 10，20 and 30 mM KCI on 
concentration-response curves to sulprostone and 17-phenyl-PGE2 was also 
investigated (Figures 3.13a and b). Synergism with sulprostone was observed for all 
three concentrations of KCI (Figure 3.13a). EC50 values for the combined 
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KCl/sulprostone curves were 5.6, 0.3 and 0.2 nM for 10，20 and 30 mM KCl 
respectively. The leftward trend of the EC50 values with increasing pre-contraction 
level was similar to that found for phenylephrine pre-contraction. Again, the 
maximum asymptotes of the three pre-contracted curves were not different with each 
other by one-factor ANOVA. 
Similar to the results obtained with phenylephrine pre-contraction, the main-effects 
between the predicted additional effect (not shown) and each corresponding KCl/17-
phenyl-PGE2 combination were not significantly different (Figure 3.13b). 
In another set of experiments, pre-contracting the preparation with a low dose of 
sulprostone (3 nM) enhanced the contractile effect of KCl. Figure 3.14 shows the 
dose-response curves of KCl constructed on basal tension and on sulprostone-
induced tone. An additive curve is calculated by adding each KCl control response 
to the contraction produced by sulprostone on preparation from the same animal. 
Mutual synergism was revealed to operate since low dose-sulprostone also enhanced 
the effect of KCl, and vice versa. 
3.3 Effect of nifedipine 
Contractions induced by KCl, phenylephrine and U-46619 were markedly inhibited 
by nifedipine. Figure 3.15 shows the effect of nifedipine on established contractions 
produced by these vasoactive agents at 40 mM, l|j.M and 30 nM respectively. The 
log IC50 values were similar, ranging from -8.39 to -8.26. About 7% of the U-46619-
induced contraction was resistant to the L-type Ca^^ channel blockade by nifedipine. 
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The maximum relaxation induced by U-46619 was significantly different from that 
. o f KCl. The contractile effects of phenylephrine and U-46619 were significantly 
inhibited by pre-treating the preparation with 100 nM nifedipine (Figures 3.16a and 
b). A greater inhibition as seen for phenylephrine compared to U-46619, agreeing 
with the post-addition profile. Nifedipine, 100 nM did not reduce the basal tone of 
the vessel. 
The synergistic effects of sulprostone with phenylephrine or KCl were also abolished 
by post addition of 100 nM nifedipine, as shown in Figure 3.17. A dose of 100 nM 
nifedipine was added to preparations contracted with the combination of 
phenylephrine (100 nM) and sulprostone (final cumulative concentration 444.4 nM). 
The vessel tone was reversed back to near basal level (Figure 3.17a). Similar effect 
of nifedipine was observed with established tone to sulprostone (3 nM)/KCl (50 mM) 
combination (Figure 3.17b). ‘ 
3.4 Effects of Rho-kinase inhibitors 
The specific Rho-kinase inhibitors Y-27632 (Uehata et aL, 1997) and H-1152 
(Sasaki et al., 2002) were used to investigate the involvement of Rho-kinase in the 
synergistic contractions produced by sulprostone and other vasoactive agents. Figure 
3.18 shows that contraction induced by 20 mM KCl was reduced by increasing 
concentrations of Y-27632. The main-effects between the pre-treatment with Y-
27632 (1 and 10 |iM) and the control were significantly different. The effects of the 
two concentrations of Y-27632 were not different when the threshold of statistical 
significance was taken as P <0.05, but a P value of 0.07 indicated that there is a 
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tendency towards statistical significance. The sensitivity to sulprostone was 
observed to decrease with Y-27632 pre-treatment; EC50 values for the 
KCl/sulprostone curves were 0.25，0.83 and 3.2 nM for the control, 1 and 10 |iM Y-
27632 respectively. The maximum effect of the KCl/sulprostone combination was 
also reduced by Y-27632. The difference between the maximum asymptotes of the 
control and 10 |iM Y-27632 was statistically significant. 
Coincident with this finding, the log concentration-response curve of KCl was 
shifted to the right with a lower maximum in the presence of 10 |J.M Y-27632 (Figure 
3.19). The synergistic effect of fixed sulprostone and KCl was also reduced by pre-
treating the preparation with 10 i^M Y-27632 (Figure 3.20). 
H-1152 was also demonstrated to dose-dependently inhibit the sulprostone- and 
phenylephrine/sulprostone-induced contractions. Figures 3.21a to d show the effect 
of 30，100，300 and 1000 nM H-1152 on the synergism between phenylephrine and 
sulprostone. Pre-treatment with 300 and 1000 nM H-1152 significantly inhibited the 
phenylephrine/sulprostone synergism. At these concentrations, effect induced by 
higher doses of sulprostone alone was also reduced. 
— Concentration-inhibition curves of the Rho-kinase inhibitors were constructed for 
other vasoactive agents (Figures 3.22 and 3.23). The IC50 values of H-1152 are 
generally lower than that of Y-27632. On the other hand, there is a portion of KCl-
induced contraction resistant to the Rho-kinase inhibition by H-1152 and Y-27632. 
The lower asymptote of the inhibition curve for Y-27632 on KCl-established tone 
was significantly different from that of U-46619 and phenylephrine (Figure 3.22). 
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However, comparing the lower asymptotes of the three inhibition curves for H-1152 
with one-way ANOVA revealed no significant difference with P = 0.08 (Figure 3.23). 
Statistical comparison of the last responses to H-1152 was also performed using one-
way ANOVA. The last points of the three curves were significantly different with P 
=0.04. 
Concentration-response curves of the Rho-kinase inhibitors were also constructed for 
inhibition of established contractions induced by phenylephrine/sulprostone (Figure 
3.24). The IC50 value of H-1152 was lower than that of Y-27632. From Figure 3.22, 
it is doubtable whether the two curves are parallel and whether the maximum 
inhibitions were the same. Unpaired t-test revealed no difference between the lower 
asymptotes for the two Rho-kinase inhibitors, with P = 0.14. In Figure 3.24c, 
absolute change in tension is plotted against concentration of the Rho-kinase 
inhibitors. The two curves are oberseved to have similar slope. It is also noteworthy 
that the IC50 values of the concentration-response curves of H-1152 for the three 
vasoactive agents were very similar (Figure 3.23) whereas for Y-27632, the IC50 
value for phenylephrine was apparently lower than those of KCl and U-46619 
(Figure 3.22). -
一 — 
It was intended to perform similar experiment with sulprostone-induced contractions. 
However, it was difficult to obtain consistent results with around 0,3 g contractions 
induced by 300 nM to l^M sulprostone. 
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3.5 Effect of EPi receptor antagonist 
Characterisation of EP3 contractile systems relies on the comparison of potencies of 
different EP3 receptor agonists due to the lack of a selective antagonist. Owing to the 
low selectivity of some commonly used agonists, it is possible to mistake an EPi 
receptor for an EP3 receptor. For example, sulprostone and 17-phenyl-PGE2 have 
EPi activities with radioligand binding K\ values of 94 and 25 nM respectively for rat 
EPi receptors expressed in HEK 293 cells. The respective values for the rat cloned 
EP3 receptor are 0.7 and 4.3 nM (Boie et al, 1997). Therefore, SC-51322, an EPi 
receptor antagonist was used in an attempt to define any contribution from EPi 
receptors present in the preparation. 
The selective EP] receptor antagonists SC-51322 at 1 p-M did not affect the 
phenylephrine-induced contractions and the subsequent addition of sulprostone and 
17-phenyl-PGE2 (Figures 3i:25a and 3.26a). On the RFA, contractions produced by 
sulprostone and 17-phenyl-PGE2 with lOOnM phenylephrine were not affected by 1 
_ )aM SC-51322 (Figures 3.25a and 3.26a). It appears that the synergisms between 
phenylephrine and the agonists were not signalled through EPi receptor activation. 
It is interesting to note that contractions produced by the higher concentrations of 
sulprostone acting alone were reduced by SC-51322, which did not occur with 17-
phenyl-PGE2, a more potent EPi receptor agonist (Figures 3.25b and 3.26b). The 
sulprostone-induced contractions (control) appear to be somewhat stronger than the 
sulprostone control obtained in other experiments of this study. Whether it is due to 
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variability between and within the animals requires further experiments. An 
equivalent volume of ethanol, the vehicle of the SC-51322 solution did not produce 
significant effect on the dose-response curves of the EP3 agonists and their synergism 
with phenylephrine (data not shown). 
To confirm the authenticity of our stock of SC-51322, it was tested against 17-
phenyl-PGE2-induced contractions on guinea-pig trachea, a typical EPi test 
preparation. SC-51322 at 10 and 100 nM shifted the log concentration-response 
curve of 1 T-phenyl-PGEi to the right in a parallel fashion (Figure 3.27). The control 
curve and the two treatment curves were used to calculate a pAz value. At about 
40% response level, dose ratios at 10'^  and 10"^M SC-51322 were 3.7 and 23.2. pA? 
values, calculated from the Schild equation: log (dose ratio-1) = log [antagonist] + 
pA2，were 8.44 and 8.35 respectively. These values agree well with the pA? value of 
8.1 determined on guinea-pig ileum (Hallinan et al., 1994). Therefore, SC-51322 is 
a potent EPi receptor antagonist that blocks 17-phenyl-PGE2-induced EPi-mediated 
smooth muscle contractions. It helps to rule out the involvement of EPi in 
contractions induced by sulprostone and 17-phenyl-PGE2 on RFA. 
3.6 Other properties of the rat femora丨 artery 
Fluprostenol, a potent and selective FP receptor agonist, at concentrations up to 4.4 
P-M failed to elicit a response on the RFA (Figure 3.28). With phenylephrine (100 
nM) pre-contraction, a small increase in tension was observed between 1.4 and 4.4 
|iM. Fluprostenol has been shown to have affinity for the human cloned EP3 receptor 
three hundred times less than that for the FP receptor (Abramovitz et al” 2000). 
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Hence, it is reasonable to suspect that the contractions induced by phenylephrine and 
fluprostenol (>1 |_iM) were mediated through the phenylephrine/EPa mechanism. 
Figure 3.29 shows the effect of U-46619 on the RFA was blocked by GR-32191, a 
specific TP receptor antagonist. The log concentration-response curve of U-46619 
was shifted to the right in a parallel fashion. GR-32191 at 1 fiM was able to inhibit 
contraction induced by lOOnM U-46619. Hence, 1 |j,M GR-32191 was present in all 
the experiments with PGE2 and its analogues to exclude any effect mediated through 
the TP receptors. 
Log concentration-response curves for the relaxant effects of the EP receptor agonists, 
AFP-07 and cicaprost on established contraction to phenylephrine are shown in 
Figure 3.30. Cicaprost produced complete relaxation, with pECso value of 8.0 士 0.1. 
AFP-07 was more potent, pECso < 9.0, but with increasing concentration complete 
relaxation was not achieved and contractile responses were produced between 40 and 
400 nM. The latter effect may be mediated through other prostanoid receptors. 
Since the TP receptor was blocked by GR-32191 and the preparation lacks EPi and 
一 FP receptors, the EP3 receptor seems lo be the most likely candidate for the effect. 
The RFA does not appear to possess DP and EP2 receptors, judging from the weak 
relaxant activity of their selective agonists, BW245C and ONO-AEl-259 (Figure 
3.31). 
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3.8 Effect of sulprostone on blood flow of rat knee joint 
Figure 3.32 shows the results of the time course experiments with sulprostone on the 
rat knee joint. All the values presented are the effect of sulprostone less the effect of 
the corresponding concentration of ethanol, the vehicle of sulprostone solution. 
Results are expressed as mean 土 SEM. Marked increase in blood flow (flux) was 
observed with 10"^  mol sulprostone between 1 and 5 min after dose addition. 
Increasing doses of sulprostone were associated with lesser increases in blood flow. 
Q Q 
The peak effects between 10" and 10' mol sulprostone were found to be 
significantly different (P < 0.05, RM-2F-AN0VA). Although significance was not 
achieved, a tendency for sulprostone to reduce blood flow immediately after dose 
addition was observed. 
Sulprostone is a selective agonist for the contractile EP receptors. It is curious to find 
that it produced vasodilatation in the vascular bed of rat knee joint. Therefore, 
_ further experiments were carried out to investigate the effect of wider range of doses 
of sulprostone to construct a dose-response curve of the preparation. Each dose of 
sulprostone was allowed to act for 15 min (see Section 2.5 for details). For each 
dose, the greatest response, no matter increase or decrease, observed was taken to 
construct a log dose-response curve as shown in Figure 3.33. It was found that 
sulprostone, at doses of 10''° and 10"^  mol significantly increased the blood flow of 
the rat knee joints. The other doses did not produce statistically significant effects on 
the blood flow. From previous time course experiments, systemic blood pressure 
was not altered after the introduction of ICT� mol sulprostone and was either 
unchanged or reduced after adding 10"^  mol sulprostone to the knee joints. Therefore, 
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the change in blood flow was a localised response to topical application of 
sulprostone at these doses. 
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2.5-| • U-46619 
• Phenylephrine 
• Sulprostone 
2-0- -p T • KCl 
0 1.5- / y --
1 i . � _ / / / 
0.0 _ ——. , . . . ”""“, 
-10 -9 -8 -7 -6 -5 -4 -3 -2 -1 
[Compound] (log M) 
Figure 3.1 Log concentration-response curves for contraction of rat femoral artery 
— by various agentsT GR-32191, 1 \xM was present in experiments with sulprostone. 
Values are mean 土 SEM (n = 5-7). 
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0.3g 
444.4 
5 min • 
144.4 fii 
PGE2 44.4 . \     
‘ 
Figure 3.2 Original chart recording depicting contractions induced by PGE2 on RPA. 
GR-32191, l)iM was present. 
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2.0-| 
• SC-46275 
1 5. • Sulprostone 
3 ‘ • 17-Phenyl-PGE2 c 
• 2 
2 1.0-•<-> c o o 
0.5-
0.0 m • , 
-10 -9 -8 -7 -6 
[PGE analogue] (log M) 
Figure 3.3 Log concentration-response curves for contraction of RFA by PGE 
analogues. GR-32191 was present in all the experiments at a concentration of 1 |aM, 
which abolished the effect of 100 nM U-46619 on RFA (see Figure 3.29). Values are 
mean 土 SEM (n = 6-7). 
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0.5g 
10 min 14.4 44.4 144.4 Sulprostone ^ ^ f • • • 
Figure 3.4 Representative trace for the phenylephrine/sulprostone synergism. 
Cumulative concentrations (nM) of sulprostone are shown. 
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3 *** 
1 1 . 0 - … 
2 T ^ - J Additive curve 
(S 0.5 态—^ 2 ^ — — P h E， 1 0 0 n M 
0.0 • • r * . ^ ^ , , 
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-0 .5� [Sulprostone] (log M) 
Figure 3.5 Log concentration-response curves of EP3 agonists (a) sulprostone, (b) 
SC-46275 and (c) 17-phenyl-PGE2, with and without pre-contraction with 100 nM 
phenylephrine. The open triangle symbols with the dashed horizontal line represent 
the contraction attained by a single dose of 100 nM phenylephrine added before 
sulprostone. The curve with open square symbols is a hypothetical additive curve as 
described in the text. Statistical comparisons of the additive and the actual pre-
contracted curves were analysed using repeated-measures twofactor ANOVA with 
pre-planned contrasts (RM-2F-AN0VA/PPC). Statistical significance is indicated 
by the asterisks: < 0.05; **P < 0.01; and ***P < 0.001. GR-32191, 1 jiM was 
present in all the experiments. Values are expressed as mean 土 SEM (n = 24-25 for 
sulprostone; 6 for SC-46275 and IT-phenyl-PGEz). 
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Figure 3.5 Continued. 
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Ig 
10 min . . . 44.4 
T r r 、 
Figure 3.6 Representative trace for the phenylephrine/17-phenyl-PGE2 synergism. 
Cumulative concentrations of IT-phenyl-PGEz in nM are shown. Note that the 
一 contractions attained after the first two doses of 17-phenyl-PGE2 were lower than 
that of phenylephrine. 
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(a) 
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-10 -9 -8 -7 -6 
u o Log [Sulprostone] (M) 
Figure 3.7 Log concentration-response curves of sulprostone with (a) 30 nM; (b) 
100 nM; and (c) 300 nM phenylephrine. The curve with open square symbols is a 
hypothetical additive curve as described in the text. Statistical comparison of the 
additive and the actual pre-contracted curves was performed using RM-2F-
ANOVA/PPC. GR-32191, 1 |iM was present in all the experiments. Values are 
expressed as mean 土 SEM (n = 6-7). 
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Figure 3.7 Continued. 
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(a) 
• Control Pre-nnntrantPd 
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(b) 
[Phenylephrine] (nM) Main effect Maximum asymptote# P = 
30 ^ 1.27 ±0.17 ^ ^ 
卜 * y Ns 
100 ：^  卜 ** 1.63 ±0.26 ：^  U s 
^ J NS 1.72 ±0.21 J NS 
) -J 
#Values are estimated from sigmoidal curves fitted by GraphPad Prism. 
Figure 3.8 Effect of varying concentrations of phenylephrine on sulprostone-
induced contractions, (a) Log concentration-response curves of sulprostone acting 
alone and with phenylephrine 30，100 and 300 nM pre-contraction. (b) Table 
showing statistical significances for the ANOVA main effects of phenylephrine pre-
contraction and the differences between the maximum asymptotes of the three pre-
contracted curves. Main effects were derived from RM-2F-AN0VA. Maximum 
asymptotes were compared using one-way ANOVA with post-hoc Bonferroni's 
multiple comparison test. GR-32191, 1 |LIM was present in all the experiments. 
Values are expressed as mean 士 SEM (n = 6-7). 
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Figure 3.9 Log concentration-response curves of 17-phenyl-PGE2 in the absence 
and presence of phenylephrine, (30，100 and 300 nM) pre-contraction. The results 
from the 300 nM phenylephrine pre-contraction experiments could not be fitted by a 
sigmoidal curve. GR-32191, 1 fj.M was present in the experiments. Results are 
presented as mean 士 SEM (n = 4-6) 
91 
Chapter 3 - Results 
+ PhE(1 OOnM)/sulprostone 
+ PhE(100nM)/SC-46275 
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Figure 3.10 Estimate of EP3 agonist synergy for sulprostone, SC-46275, 17-phenyl-
PGE2 and fluprostenol. Each contraction induced by the combination of 100 nM 
phenylephrine and the EP3 agonists was divided by the hypothetical additive value. — 
The additive value is the sum of the contractions produced by 100 nM phenylephrine 
and corresponding response to the EP3 agonist alone on vessel rings from the same 
animal. Values are mean 士 SEM. 
92 
Chapter 3 - Results 
144. 4444 
�.2g L 44.4 
5 min J M 
14.4 / 
PGEz 4.4 . / 04 1-4 I I / 
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_ 30mM • y 
Figure 3.11 Representative trace for the KCI/PGE2 synergism. Cumulative 
concentrations (nM) of PGE2 are shown. 
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‘ Figure 3.12 Log concentration-response curves of EP3 agonists: (a) sulprostone, (b) 
SC-46275 and (c) 17-phenyl-PGE2, with and without pre-contraction with 20 mM 
KCL The curve with open square symbols is a hypothetical additive curve as 
described in the text. RM-2F-AN0VA/PPC was used to compare the additive and 
the actual pre-contracted curves. GR-32191, 1 \iM was present in all the experiments. 
Values are expressed as mean 土 SEM (n = 5). 
94 
Chapter 3 - Results 
(b) 
• Control o c_ 
1 • KCI(20mM)-pre-contracted 
* * * * * * * * * 
2 . 0 - J 丁 丁 
•I ； Z 
2 1.0- T X I 
g X T • — — A d d i t i v e curve 
。 0 . 5 - 壬 - - - - - - - I • — J KCl, 20mM 
0.0 . — — • ~ ~ ^ ^——, , 1 
-10 -9 -8 -7 -6 
-0.5」 [SC"46275] (log M) 
(c) 
• Control 
2-5i • KCl (20mM)-pre-contracted 
2 . 0 - ** 
• • 
卜 T -
o T ^ ^ Additive curve 2 1.0- T _ 丁 
^ 丄 -— - L - - A ^ KCl, 20mM 
Q 0 . 5 - 丄 丄 丄 一 丄 
一 _ 0.0 , • • • • r * ^ • , 
-10 -9 -8 -7 -6 
-0.5� [17-Phenyl-PGE2] (log M) — 
Figure 3.12 Continued. 
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Figure 3.13 Log concentration curves of (a) sulprostone and (b) 17-phenyl-PGE2 
with varying KCl pre-contraction levels. GR-32191, 1 was present in all the 
experiments. Values are mean 士 SEM (n = 4-5). 
96 
Chapter 3 - Results 
• Control 
2.5-1 • Sulprostone-pre-contracted 
*** ** 
* * * 丁 T 
2.0-
* * * f  
3 T/^ 丄 丁 
g 1.5_ / J ——Additive curve 
3 0.5- ^ S / 
0.0- ^ Sulprostone, 3nM 
^ ^ ^ ^ ^.0 
- 0 . 5 � 
[KCI] (log M) 
Figure 3.14 Log concentration-response curves of KCI with and without pre-
contraction with 3 nM sulprostone. The curve with open square symbols is a 
hypothetical additive curve as described in the text. Statistical comparison of the 
additive and the pre-contracted curves was performed using RM-2F-ANOVA/PPC. 
Values are expressed as mean 士 SEM (n = 5). 
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Figure 3.15 (a) Log concentration-inhibition curves of nifedipine on established 
contractions to vasoactive agents on RPA. The upper asymptotes of the fitted 
sigmoidal curve were constrained to 100%. (b) One-way ANOVA with post-hoc 
Bonferroni's multiple comparison test was used to compare the IC50 and the lower 
asymptote of the curves. Results are expressed as mean 土 SEM (n = 4-5). 
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Figure 3.16 Log concentration-response curves of (a) phenylephrine and (b) U-
46619 in the absence and presence of nifedipine. Nifedipine, 100 nM was added to 
the organ bath 10 min before the first dose of agonist. Values are expressed as mean 
士 SEM (n = 5). 
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Figure 3.17 Effect of nifedipine one established responses to combinations of 
contractile agents, (a) Phenylephrine (100 nM) and sulprostone (final cumulative 
concentration 44.4 nM) (n = 7) and (b) sulprostone (3nM) and KCl (final cumulative 
concentration 50 mM) (n = 4). Statistical analysis using paired t-test was performed. 
Results are mean 士 SEM 
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• Y-27632，10|_iM 
2.0- J I t i i 
3 ‘ K C I (?nmM) 
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[Sulprostone] (log M) 
(b) 
Pre-treatment Main effect Maximum asymptote P = 
H ^ ^ ” I 1.27 ±0.17 ^ 
卜 * y NS Y-27632, 1 nM � ^ *** 1.63 ± 0.26 ^ L * 
Y-27632, 10 )iM } N S J 1.72 ±0.21 J ^^ J 
Values are estimated from sigmoidal curves fitted by GrapPad Prism. 
Figure 3.18 (a) Log concentration-response curves of sulprostone pre-contracted 
with 20 mM KCI, pre-treated with Y-27632. Y-27632, 1 or 10 pM or equivalent 
volume of water, the solvent was added to the organ bath 10 min before 20niM KCI. 
(b) RM-2F-AN0VA was used to analyse the difference between the main-effects of 
Y-27632 treatments and the control. The KCI dose results were included in the 
statistical analysis. Maximum asymptotes were compared using one-way ANOVA 
with post-hoc Bonferroni's multiple comparison test. GR-32191, 1 |_iM was present 
in the experiments. Values are mean 士 SEM (n = 4). 
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Figure 3.19 Log concentration-response curves of KCl in the absence and presence 
of Y-27632. Y-27632, 10 i^M was introduced 10 min prior to the first dose of KCl. 
Values are mean 士 SEM (n = 5). 
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Figure 3.20 Log concentration-response curves of sulprostone/KCl with and without 
Y-27632. Y-27632, 10 fiM was introduced 10 min prior to sulprostone, 3 nM. 
Values are expressed as mean 土 SEM (n = 4-5). 
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Figure 3.21 Concentration-dependent effect of H-1152 on 
phenylephrine/sulprostone synergism. RM-2F-ANOVA revealed no effect of H-
1152 (30 nM - 1 |iM) on concentration-response curves of sulprostone only. H-1152 
at higher doses (0.3 - 1 |J,M) produced significant effect on the 
phenylephrine/sulprostone-induced contractions. Results are expressed as mean 士 
SEM (n = 5-7). 
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Figure 3.21 Continued. 
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#Values were estimated from sigmoidal curves fitted by GraphPad Prism software. 
3.22 (a) Log concentration-response curves of Y-27632 on established contractions 
to vasoactive agents on RFA. The upper asymptote of the fitted sigmoidal curve was 
constrained to 100%. (b) One-way ANOVA with post-hoc Bonferroni's multiple 
comparison test was used to compare the IC50 and lower asymptotes of the curves. 
Values are expressed as mean 士 SEM (n = 6). 
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(b) 
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林 Values were estimated from sigmoidal curves fitted by GraphPad Prism software. 
Figure 3.23 (a) Log concentration-response curves of H-1152 on established 
contractions to vasoactive agents on RPA. The upper asymptote of the fitted 
sigmoidal curve was constrained to 100%. (b) One-way ANOVA with post-hoc 
Bonferroni's multiple comparison test was used to compare the IC50 and lower 
asymptote of the curves. Values are expressed as mean 士 SEM (n = 5). 
107 
Chapter 3 - Results 
(a) 
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Values were estimated from sigmoidal curves fitted by GraphPad Prism software. 
Figure 3.24 (a) Log concentration-response curves of Rho-kinase inhibitors on 
established contractions to phenylephrine/sulprostone on RFA. The upper asymptote 
of the fitted sigmoidal curve was constrained to 100%. (b) Two-tailed unpaired t-test 
was used to compare the lower asymptotes of the curves, (c) Log concentration-
response curves of Rho-kinase inhibitors on established contractions to 
phenylephrine/sulprostone with contraction expressed as absolute change in tension. 
GR-32191, 1 fj,M was present in the experiments. Results are presented as mean 士 
SEM (n = 6). 
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Figure 3.25 Effect of SC-51322 on the log concentration-response curve of 
sulprostone (a) with and (b) without phenylephrine pre-contraction. GR-32191，1 
i^M was present in all experiments. Values are presented as mean 士 SEM (n = 6-8). 
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Figure 3.26 Effect of SC-51322 on the log concentration-response curve of 17-
phenyl-PGE2 (a) with and (b) without phenylephrine pre-contraction. GR-32191, 1 
|iM was present in all experiments. Values are presented as mean 士 SEM (n = 4-5). 
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Figure 3.27 Log concentration-response curves of 17-phenyl-PGE2 for contraction 
of the guinea-pig isolated trachea with and without pre-treatment with SC-51322. 
SC-51322, 10 or 100 nM or an equivalent volume of ethanol, the vehicle was added 
to the organ bath 30 min before 17-phenyl-PGE2. The tension changes were 
normalised to the contraction induced by 10 |iM ACh. Values are mean 士 SEM (n = 
4). RM-2F-AN0VA detected no difference between the Control and Ethanol control 
_ curves. 
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Figure 3.28 Log concentration-response curve of fluprostenol with and without 
phenylephrine pre-contraction. Values are obtained from one experiment. 
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Figure 3.29 Log concentration curve of U-46619 and effect of GR-32191. Values 
are obtained from one experiment. 
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Figure 3.30 Log concentration-response curve of IP receptor agonists cicaprost and 
AFP-07 on established contractions to phenylephrine (300 nM). GR-32191, 1 |aM 
一 was pr^ent in the experiments. Results are presented as mean 士 SEM (n = 4). 
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Figure 3.31 Log concentration curve of the selective EP2 receptor agonist ONO-
AE1-259 and the DP receptor agonist BW245C on established contractions to 300 
nM phenylephrine. GR-32191, 1 jiM was present. Values are mean 士 SEM (n = 4). 
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Figure 3.32 Effect of 10" and 10' mol sulprostone on rat knee joint blood flow over 
15 min. RM-2F-ANOVA/PPC was used to compare the curves of 10"^  mol 
sulprostone against that of 10'^  mol, which were found to be significantly different {P 
=0.26). Statistical significance is indicated by the asterisks: *P < 0.05; **P < 0.01; 
and < 0.001. All the values presented are the effect of sulprostone less the 
- effect of the corresponding concentration of ethanol (vehicle). Results are expressed 
as mean 士 SEM (n = 8 - 16). 
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Figure 3.33 Log dose-response curve of sulprostone on blood flow of rat knee joint. 
Results are the maximum change in blood flow (increase or decrease) to each dose of 
sulprostone within 15 min. Statistical comparisons of the responses to each dose of -
sulprostone and the basal level were analysed using one-factor ANOVA with post 
hoc Bonferroni's multiple comparison test. Statistical significance is indicated by 
the asterisks: < 0.05; < 0.01; and ***P < 0.001. All the values presented are 
the effect of sulprostone less the effect of the corresponding concentration of ethanol 
(vehicle). Results are expressed as mean 士 SEM. (n = 8). 
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Chapter 4 Discussion 
4.1 Effect of PGE analogues on rat femoral artery 
This study demonstrated that PGE2 and its analogues induced vasoconstriction of the 
isolated rat femoral artery (RFA) through EP3 agonism. The contractions activated 
by the PGE analogues were less than one sixth of the U-46619 maximum, but were 
enhanced by pre-contracting the vessel with other agents such as KCl and 
phenylephrine. The synergistic actions between the PGE analogues and KCl or 
phenyleprhine were inhibited by nifedipine and Rho-kinase inhibitors. 
4.1.1 Prostanoid receptor(s) responsible for the contractile effects 
On the RFA, PGE2, sulprostone, SC-46275 and IV-phenyl-PGEz produced 
contraction in the presence of the COX inhibitor indomethacin and the TP receptor 
antagonist GR-32191. Hence, these contractions were neither influenced by 
endogenous production of prostanoids nor due to cross activation of TP receptors. 
Table 4.1 shows the potencies of some prostanoids used in this study and on some 
EP3 systems. 
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Table 4.1 Upper panel shows the equi-effective molar ratios of prostanoids on EP3 
systems. Lower panel shows the relative binding affinities of these prostanoids on 
recombinant EP3 receptors. 
System P G E 2 SC-46275 Sulprostone 17- Fluprostenol 
Phenyl 
- P G E 2 
Isolated tissues Equi-effective molar ratios 
Guinea-pig aorta 5A 0.11 ITo f ^ >250 
(Jones etal., 1998) (23 nM) 
Guinea-pig vas 1 4 LO NT NT 
deferens (1.6 nM) 
(Savage et al., 1993) 
Guinea-pig vas ^ NT LO ^ NT 
deferens (0.2 nM) 
(Lawrence et al.’ 1992) _ 
Rat femoral artery NT 0 4 LO 1L6 NT 
Binding assays Relative binding affinity (K{) 
- Human EP3-111 0 9 [NT HLO [NT «2000 
recombinant receptor (0.35 nM) 
(Abramovitz et al., ‘ 
_ 2000) 
Mouse EP3a "NT LO "NT "NT ' 
recombinant receptor (0.6 nM) 
(Kiriyama一e/flf/., 1997) 
Rat EPsa r e c o m b i n a n t L 3 NT LO ^ NT 
receptor (0.7 nM) 
(Boie et al., 1997) 
NT: not tested. In each case, sulprostone is the standard agonist (= 1.0); its EC50/IC50 
is given in parenthesis. 
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It was crucial to have a TP antagonist present since some PGE analogues show 
pronounced TP agonism. For example, ICI-80205 and 16,16-dimethyl PGE2 
contracted isolated preparations of rabbit aorta and dog saphenous vein and these 
effects were abolished by TP receptor antagonist (Jones et al., 1982). In my 
experiments, GR-32191 was used; it usually behaves as a competitive antagonist 
with pA2 values in the range 8.3 to 8.7 (Lumley et al, 1989). On RFA, its pA2 was 
about 7.8，and a concentration of 1 would afford a dose-ratio of 56. This would 
be more than adequate to abolish any TP agonism of the PGE analogues examined. 
The low potency of fluprostenol on the RFA excludes the effects of the PGE 
analogues on FP receptors. Fluprostenol is the most selective FP agonist reported to 
date. It is preferred to cloprostenol, which has significantly higher EPi and EP3 
binding affinity (Abramovitz et al” 2000). Therefore, the contraction induced by 
PGE2 and its analogues appear to be due to activation of EP receptor(s). 
A marked fade was observed following the phasic contraction with high dose PGE2 
(Figure 3.2). It might be due to functional antagonism, whereby PGE2 activates 
relaxant EP receptors or even other prostanoid receptors. The negligible effect o f -
ONO-AE1-259, a selective EP2 receptor agonist indicates that the EP2 receptor is 
absent from the RFA, leaving the possibility of EP4 involvement. Unfortunately, a 
selective EP4 agonist was not available. Recently, the ONO Pharmaceutical 
Company has developed a selective EP4 agonist (Cao et al., 2002; Inoue et al, 2002), 
but full details of its agonist potencies on the classical functional preparations have 
not been published. The IP receptor is another candidate for the fade. AFP-07 was 
about 10 times more potent than cicaprost in relaxing the RFA; this is consistent with 
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Studies on IP systems in guinea-pig aorta (12-fold more potent), piglet carotid artery 
(9-fold) and rabbit mesenteric artery (9-fold) (Jones et al, 2001). However, PGE2 
has been shown to have poor binding affinity for the IP receptors (Abramovitz et al., 
2000; Kiriyama et al., 1997). The reversal of relaxation with increasing 
concentration of AFP-07 may be due to EP3 agonism. Although Chang et al (1997) 
claimed AFP-07 to be highly selective for the IP receptor, examination of their 
competitive binding curves reveals displacement of [^H]PGE2 from the mouse 
recombinant EP3 receptor with K�of about 300 nM (Chang et al., 1997). 
The DP receptor is not likely to have taken part since PGE2 has negligible binding 
affinity for the recombinant rat DP receptor with K[ value > 1 |_iM (Wright et al., 
1999). Moreover, the DP receptor appears to be absent from the RFA as shown by 
the lack of effect of the selective DP receptor agonist BW245C. 
So the major question we have to resolve is whether the PGE analogues activate EPi 
or EP3 receptors in RFA to cause contraction. Sulprostone and 17-phenyl-PGE2 are 
active at both EPi and EP3 receptors; with sulprostone being more active at EP3 than 
EPi recepter, while the reverse is true for 17-phenyl-PGE2 (Lawrence et al,, 1992). 
On the other hand, SC-46275 is the most selective EP3 receptor agonist documented 
to date (Savage et al., 1993). It has very low activity at the EPi subtype. At 30 |j,M, 
SC-46275 induced only 33% of the maximal contraction produced by PGE2 and 
sulprostone on the guinea-pig ileal longitudinal muscle, which is a typical EPi-
containing preparation (Savage et al., 1993). In this study, the potency of SC-46275 
to induce contraction was greater than that of sulprostone, indicating the identity of 
the EP receptor involved was predominantly of the EP3 subtype. 
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4.1.2 Prostanoid Receptors involved in the synergism 
The weak contractions induced by PGE2, sulprostone, SC-46275 and to a lesser 
extent 17-phenyl-PGE2 were enhanced by pre-contracting the vessel with another 
vasoactive agent like phenylephrine and KCl. On the other hand, the potentiation of 
KCl responses by pre-contraction with threshold dose of sulprostone suggests that 
the synergism take place irrespective of the order of exposure to the agents. In other 
words, the synergism is mutual, a not unexpected finding. 
The phenylephrine/sulprostone and phenylephrine/SC-46275 combinations produced 
contractions equivalent to 4 times the sum of their responses when acting alone. The 
sensitivity to sulprostone was found to be increased by increasing pre-contractions 
with phenylephrine and KCl. The profile of IT-phenyl-PGEi was somewhat 
different to those of sulprostone and SC-46275. With low and moderate 
phenylephrine pre-contraction, synergism with sulprostone was clearly evident. 
Furthermore, pre-contraction with phenylephrine unmasked an action of fluprostenol 
at micromolar concentrations. It is believed to be a synergism mediated through EP3 
rather than FP receptors as fluprostenol has an affinity for the cloned human EP3 
receptor 300 times less for the FP receptor. _ 
Synergism with sulprostone was observed for varying degree of pre-contraction 
induced by 30，100 and 300 nM phenylephrine (Figure 3.8). The maximum 
asymptotes of the three pre-contracted curves were found not to be significantly 
different. The maximum asymptotes of the 100 nM phenylephrine/sulprostone and 
300nM phenylephrine/sulprostone curves are around 1.6 g. It appeared that the 
maximum capacity of the ai/EPj synergism in the RFA is about 1.6 g. The effect of 
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17-phenyl-PGE2 was not enhanced by pre-contracting the vessel with 300 nM 
phenylephrine (Figure 3.9). However, it is noteworthy that the contraction produced 
by 300 nM phenylephrine in these experiments had already approached 1.6 g. 
Therefore, the effect of 17-phenyl-PGE2 might be limited by the capacity of the 
ai/EP3 synergism. On the other hand, 1.6 g is the limit for the ai/EPs synergism but 
not the maximum contractile response of the tissue; U-46619-induced contractions 
exceeded this level (Figures 3.1 and 3.29). 
There is a reasonably good correlation between the potencies of the prostanoids to 
induce overt contraction and to synergise with phenylephrine. However, the 
experiments described so far do not exclude a contribution from EP! receptors. This 
was examined using SC-51322, a selective EP! antagonist. SC-51322 is the most 
potent of a series of dibenzoxazepine analogues with EPi receptor blocking and 
analgesic properties. SC-19220，the first reported analogue has a pA2 of 5.6 for the 
EPi receptor. SC-51322 has a reported p A � o f 8.1 determined on guinea-pig ileum 
(Hallinan et al, 1994). Recently, SC-51322 was reported to hav^a pKe value of 8.8 
in a reporter gene assay in HEK 293 EBNA cells expressing EPi receptors (Durocher 
et al” 2000). -
The contraction profiles of phenylephrine/sulprostone and phenylephrine/17-phenyl-
PGE2 were not altered by the application of SC-51322. Therefore, by eliminating the 
effect of EPi, TP and FP receptors, the synergistic effects of the EP3 receptor 
agonists and phenylephrine or KCl were evidently mediated through the EP3 receptor 
subtype. 
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4.1.3 Synergism models 
Two agonists acting at different receptors in the same system may activate the same 
or different transduction mechanisms. Leff has proposed a theoretical model of 
threshold synergy applied to two receptors that interact with a common transducer 
process (Leff, 1987). The two-receptor-one-transducer model predicts mutual 
potentiation between agonists, which can be quantified from the shapes of the 
individual concentration-response curves. When agonist A is potentiated by the 
presence of a fixed low concentration of agonist B, the concentration-response curve 
is shifted to the left with a reduced EC50. However, when larger responses are 
induced by higher concentration of agonist B, the concentration-response curve of A 
will be displaced to the right and the EC50 value is increased. It should be noted that 
the shifts in the EC50 values, particularly the left-shifts, were quite small in the 
systems that Leff studied. For the histamine/5-HT interaction in the rabbit aorta, the 
EC50 values for 5-HT were 240 (zero histamine), 132 (3 \iM histamine) and 263nM 
— (lOfiM histamine). The EC50 values for histamine in the presence of 5-HT were 4.0 
(zero 5-HT), 1.7 (0.3 i^M 5-HT) and 4.0^M (1 |iM 5-HT) (Leff, 1987), 
The shapes of the concentration-response curves for the EP3 agonists and 
phenylephrine or K+ are quite different, and two explanations readily come to mind. 
Firstly, it is possible that there are very few EP3 receptors in the preparations. Thus 
although the EP3 receptor may share the same transducer mechanisms as 
phenylephrine and K+，maximal occupancy of the EP3 receptors pool will produce 
only a small biological stimulus (the primary input from the receptor / G protein 
interaction). Alternatively, there may be an abundance of EP3 receptors in the 
preparation, but they couple to a transduction system different to those activated by 
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phenylephrine and K+ and which can only generate a limited contractile force. I 
favour the latter explanation since the marked synergism observed is not consistent 
with the Leff's model. Indeed, it is consistent with the established evidence that the 
EP3 receptor couples to Gj resulting in adenylate cyclase inhibition and the cci-
adrenoreceptor couples to Gq protein leading to Ca^^ mobilization. In addition, in the 
RFA, the EC50 of sulprostone was shown to be lower with higher phenylephrine pre-
contraction. Therefore, the synergism profiles described in this study do not accord 
with Leff's two-receptor-one-transducer model. 
Large synergistic interactions between agonists mediating vasoconstriction through 
I 
different receptors have been observed in several vascular systems. By pre-
activating the rat tail artery by vasopressin, Lew and Flanders (1999) exposed the 
otherwise silent melatonin-induced vasoconstriction. The authors put forward a 
theory of threshold inertia to account for the synergism between strong and weak 
vasoconstrictors in vitro. 
'Effector reserve' which is the centre of the theory is thought to be a factor 
determining the strength of a constrictor system. The term refers to the inertia a 
stimulus has to overcome before producing an overt contractile response (Lew et al., 
1999). If we use the theory to explain the synergism on the RFA, pre-contraction 
with phenylephrine or KCl overcomes the inertia so that the total effect of 
sulprostone or other EP3 agonists could be converted to observable contraction. On 
the other hand, KCl-induced response was enhanced by low dose sulprostone which 
merely overcame the threshold inertia. 
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Threshold inertia may have explained some aspects of the synergism. However, 
ignoring the involvement of signal transduction mechanisms would oversimplify the 
interactions. 
4.2 Mechanisms of synergistic contractions 
4.2.1 Role of Ca2+influx 
For the contractions induced by vasoactive agents alone and the 
phenylephrine/sulprostone and sulprostone/KCl combinations, the importance of 
Ca2+ influx through L-type Ca^^ channels is apparent from the sensitivity of the 
contractions to nifedipine. In many smooth muscle preparations, micromolar 
concentrations of nifedipine are often used, raising doubts as to the specificity of 
action. However, in the RFA, nifedipine, at 100 nM was able to abolish the _ 
contractions induced by KCl and phenylephrine as well as their synergistic 
combination with sulprostone. In isolated rat aorta, Huang and Ho found that 
nifedipine at 5 nM entirely inhibited contraction attributed to Ca^^ through VDCCs 
but up to 1 |.iM did not affect the receptor-operated Ca^ "^  channels (Huang & Ho， 
1996). Therefore, it would seem reasonable to suppose that nifedipine at 100 nM is 
simply blocking L-type channels in RFA. 
On the other hand, a portion of the U-46619-induced contraction was observed to be 
resistant to nifedipine. U-46619 is a TP receptor agonist. TP receptor is known to 
couple to Gq protein and release intracellular Ca^ "*" by IP3 (Breyer et al., 2001; 
Coleman et al,’ 1994). In addition it has been shown to induce greater Ca^ "^  
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sensitizing action than phenylephrine and K+ (Himpens et al., 1990). Therefore, the 
contribution of Ca^^ influx to contraction induced by U-46619 might not be as 
important compared with phenylephrine and KCl in the RFA. 
4.2.2 Role of Ca2+ sensitization 
The Rho-kinase inhibitors Y-27632 and H-1152 were shown to inhibit the 
contractions induced by vasoactive agents. U-46619, a potent Ca^ "^  sensitizing 
vasoconstrictor (Himpens et al” 1990), was inhibited by Y-27632 and H-1152 with 
IC50 values of 1.4 and 0.13 |LIM respectively. However, these potencies, especially 
for H-1152, are weaker than their reported K�values of 0.14 [iM and 0.16 nM 
respectively (Sasaki et al., 2002; Uehata et al, 1997). 
Similar potency of Y-27632 has been reported in another isolated artery preparation. 
In human internal mammary artery, Y-27632 inhibited the U-46619 (10 nM)-
established contraction with IC50 value of 1.67 (Batchelor et al., 2001), which 
agrees well with the findings in the RFA. U-46619-induced MLC phosphorylation 
and shape change of platelets were also found to be inhibited by Y-27632 (Klages et 
al.’ 1999). Y-27632 at 30 [xM fully inhibited the shape change of wild-type platelet. 
A lower concentration (10 jj.M) was sufficient to inhibit the shape change of Gq-
deficient platelets. C3 exoenzyme, an inhibitor of Rho also inhibited the platelet 
shape change in the Gq-deficient platelets. Moreover, Y-27632 and C3 inhibited the 
U-46619-mediated phosphorylation of MLC. These inhibitory effects were more 
pronounced in the Gq-deficient platelets than the wild-type. G12 and Gn were the 
only G proteins that coupled to the TP receptors in these Gq-deficient platelets. 
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Therefore, that platelet shape change and MLC phosphorylation mediated by TP 
receptors on platelets involved activation of the Rho/Rho-kinase pathway via G12/13 
proteins was suggested. The inhibition of MLC phosphorylation by C3 was found to 
be incomplete. The author suggested that it was due to incomplete inhibition of Rho 
by C3 (Klages et al” 1999). 
Recently, Ito and co-workers reported that another prostanoid, PGF2a induced 
contraction and MLC phosphorylation of rabbit aorta at constant [Ca^^]/ via a Rho-
kinase-dependent pathway. PGF2a was shown to raise [Ca2+]/ by Ca^ "^  influx through 
L-type Ca2+ channels. In the absence of extracellular Ca^ "^ , however, PGF2a was also 
able to induce contraction and MLC phosphorylation. Y-27632, HA-1077 (fasudil) 
and hydrofasudil were found to inhibit the PGF2a (3 |J,M)-induced contraction with 
IC50 values of 0.85 and 3.7 and 4.0 |aM respectively (Ito et aL, 2003). All three 
agents were also shown to inhibit MLC phosphorylation. These Rho-kinase 
inhibitors display different kinase inhibition selectivity, but they all potently inhibit 
Rho-kinase. Therefore, the results strongly suggested that the effect was mediated by 
Rho-kinase but not other kinases such as PKA, PKC and MLCK. 
From our experiments, H-1] 52 inhibited the phenylephrine/sulprostone combinations 
dose-dependently. The inhibition was more prominent at lower concentration of 
sulprostone. As the sulprostone concentration increased, the influence of Rho-kinase 
inhibition decreased proportionately. A similar trend was observed with the 
KCl/sulprostone combination attenuated by 10 }iM Y-27632. It may indicate 
multiple signalling systems contributing to the synergistic actions of sulprostone and 
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Other agents and the relative importance of these systems changes over different 
concentrations of agonists. 
The experimental evidence presented indicates the contractions produced by 
phenylephrine or KCl and sulprostone were dependent on Rho-kinase-mediated 
process as well as Ca^^ influx through L-type Ca^ "^  channels. How can these 
seemingly contradictory mechanisms interact with the cellular contractile machinery? 
In an attempt to explain the actions of Ca^^-dependent and the Ca^^-sensitization 
pathways in the synergism, a hypothetical scheme is proposed in Figure 4.1. 
Contraction of the vascular smooth muscle is believed to be controlled by the 
phosphorylation state of the myosin light chain (MLC), which is determined by the 
balance between the activities of the myosin light chain kinase (MLCK) and the 
myosin phosphatase. The association of calcium-calmodulin complex and the 
catalytic subunit of MLCK stimulate the phosphorylation of the Ser 19 residue of the 
MLC, leading to contraction. On the contrary, raising the activity of myosin 
phosphatase promotes the dephosphorylation of MLC, thereby inhibiting contraction 
(Somlyo et al, 1994). 
High extracellular [K+] depolarizes the plasma membrane and therefore opens the L-
type Ca2+ channels. The resultant increase in [Ca^ "^ ]/ phosphorylates MLC via 
MLCK and causes contraction. Therefore, nifedipine readily blocked the KCl-
induced contractions. Phenylephrine activates ai receptor which is known to couple 
to Gq protein. InsPs released upon hydrolysis of PLC activates the release of Ca^^ 
from the sarcoplasmic reticulum. The elevated [Ca^ "^ ]/ by the release activates the 
129 
Chapter 4 - Discussion 
phosphorylation of MLC. Alternatively or additionally, the InsPs-released Ca^^ may 
activate Ca^"^-dependent conductances in the plasma membrane such as Ca^ "^ -
dependent CI" channels and non-specific cation channels. Depolarization of the 
plasma membrane is a consequence of the activation of these channels, which opens 
^ . 
the L-type Ca channels. This can explain why phenylephrine-induced contraction 
was also readily blocked by the action of nifedipine. 
The existence of alternatively spliced isoforms for the EP3 receptor subtype has been 
illustrated in many studies (see Section 1.1.1.3). The various EP3 receptor isoforms 
have been demonstrated to universally couple to Gi protein. In addition, coupling to 
other G proteins by some of the isoforms have been demonstrated. Katoh and co-
workers showed that the bovine EP3B isoform might regulate the morphology of 
neuronal cell through a Rho-dependent pathway via G12/13 (Katoh et al., 1996). 
Therefore, the possibility that the EP3 receptors on the RFA couple to multiple signal 
transduction pathways cannot be overlooked. A causative relationship between the 
EP3 receptor and the Rho/Rho-kinase pathway may explain the weak contraction — 
profiles of the EP3 receptor agonists on the RFA. Once contraction is induced by 
either KCI and phenylephrine via mechanisms described above, the raised [Ca�.]/ 
increases the activity of MLCK, which works synergistically with the Rho-kinase-
mediated attenuation of myosin phosphatase activity. Enhanced contraction is the 
result. This proposal can also account for the enhanced effect by adding KCI to 
vessel pre-contracted with low dose sulprostone. 
When the contractile force was increased by increasing sulprostone concentration, 
the proportion of force that was sensitive to Rho-kinase inhibition diminished. This 
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might be due to the multiplicity of EP3 coupling to G proteins. Coupling to Gj 
protein is a well-recognised pathway of EP3 receptors. Activation of EP3 leads to a 
reduction in cAMP production and PKA activation, thereby lifting the inhibitory 
effect of PKA on MLCK, MLCK was shown to be phosphorylated by PKA subunit 
in turkey gizzard smooth muscle (Adelstein et al., 1978) and the phosphorylation 
sites for PKA have been identified (Conti et al., 1981). Phosphorylation of MLCK 
was demonstrated to reduce Ca^ "^  sensitivity of MLC phosphorylation and increase 
the amount of Ca^+Zcalmodulin required for the kinase activity (Adelstein et al., 1982; 
Conti et al” 1981). 
Following on the hypothesis, when the sulprostone-mediated Rho-kinase activation 
is inhibited by H-1152, increasing concentration of sulprostone may recruit more 
transduction pathways such as the inhibition of adenylate cyclase. As a result the 
synergistic action of phenylephrine and higher concentration of sulprostone is less 
susceptible to Rho-kinase inhibition since other mechanism, for example the 
disinhibition of MLCK by reducing PKA can also work synergistically with the 
Ca2+-dependent pathways. Of course the assumption here is that a basally active 
_ adenylate cyclase system produces sufficient cAMP to produce a continuous 
inhibitory input to the smooth muscle cell or adenylate cyclase is activated during 
contraction elicited by an excitatory agonist, perhaps as a negative feedback 
mechanism. 
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4.3 Effect of sulprostone in vivo 
Sulprostone given intravenously was reported to be an effective drug in the 
termination of second and third trimester pregnancies in a study with 284 women 
with intrauterine foetal death or foetal abnormalities (de Boer et al., 2001). In 
addition, intramuscular sulprostone has been used in the management of post-partum 
haemorrhage and was demonstrated to effectively prevent post partum blood loss in a 
randomized, placebo controlled, double-blind trial (Poeschmann et al., 1991). The 
side-effects profiles of sulprostone in these studies were generally acceptable. 
However, serious cardiovascular side effects such as coronary artery spasm (Ulmann 
et al, 1992) and critical limb ischaemia (de Koning et al., 1995) have been reported. 
In view of vasoconstrictor effect of sulprostone from in vitro studies and the 
cardiovascular effects reported in the clinical studies, it is interesting to find that 
sulprostone did not exhibit significant vasoconstriction of the vascular bed of rat 
knee joint. In contrast, and 10"^  mol sulprostone caused an elevation in rat knee 
joint blood flow. 
Sulprostone is shown to induce weak contractions of the rat femoral artery (RFA) in 
this study. In fact, sulprostone has been demonstrated to induce contractions weaker 
than the tissue maximum in other in vitro preparations such as the guinea-pig aorta 
(Jones et al., 2002), human pulmonary artery (Qian et al., 1994) and rabbit renal 
artery (Ahluwalia et al” 1988). The sulprostone-induced responses in both RFA and 
guinea-pig aorta were enhanced by pre-contracting the vessel with a vasoactive agent 
(this study and Jones et al., 2002). Therefore, the insignificant vasoconstrictor 
characteristic of sulprostone in the normal rat knee joint may be analogous to the 
non-pre-contracted state in vitro. If the vascular bed of the rat knee joint is pre-
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contracted with a vasoactive agent, sulprostone may possibly display more potent 
vasoconstrictor activity. This will require further experiments to confirm. If this 
hypothesis is true, the sulprostone-induced adverse effect in clinical reports described 
above may be a consequence of an ‘exaggerate’ contractile effect of sulprostone in 
blood vessel that is already partially constricted by a pre-existing physiological or 
pathophysiological state. 
Sulprostone is a selective EP3 receptor agonist. It also binds to other receptors like 
EPi and FP receptors (Abramovitz et al., 2000). All of these receptors are known to 
mediate vasoconstriction and sulprostone does not appear to have effect on 
prostanoid receptors mediating relaxant properties. Therefore, it is surprising to 
found that sulprostone caused an increase in rat knee joint blood flow. In the rat 
knee joint experiments, L-NAME and indomethacin were not used as in the in vitro 
experiments. Nevertheless, the sulprostone-induced vasodilatory effect is not likely • 
to be a direct EPs-mediated effect. It might be due to another factor that was 
modulated by EP3 receptor activation. Sympathetic noradrenaline release has been 
shown to be inhibited by sulprostone and other PGE analogues via pre-synaptic EP3 
receptors in several preparations^ including the rat vena cava, human saphenous vein, 
pulmonary artery and right atrial appendages (Molderings et cd., 1992; Molderings et 
al, 1994; Molderings et al, 1998). Therefore, it is possible that sulprostone caused 
vasodilation of the knee joint vasculature by reducing noradrenaline release via 
inhibitory pre-synaptic EP3 receptors. Moreover, phentolamine, an a-adrenoceptor 
antagonist, has been shown to increase blood flow of the rat knee joint (Prof. F Lam, 
personal communication). Thus, the sulprostone-induced vasodilatation in rat knee 
joint might be mediated by reduced activation of post-synaptic a-adrenoceptor. 
133 
Chapter 4 - Discussion 
However, the maximum increase of blood flow by phentolamine was around 11%, 
whereas 10'^  sulprostone caused over 80% increase in blood flow as observed in this 
study. Other mechanisms might have come into play, requiring further investigations. 
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Figure 4.1 Schematic diagram depicting the mechanisms proposed for the 
p h e n y l e p h r i n e / s u l p r o s t o n e synergism in the RFA. G proteins are not drawn. See 
text for description. AC: adenylate cyclase; CaM: calmodulin; MP: myosin 
phosphatase; SR: sarcoplasmic reticulum. 
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4.4 Conclusion 
This study has demonstrated that in rat femoral artery (RFA), PGE analogue-induced 
weak contractile effect was enhanced by pre-exposing the vessel to a strong 
vasoactive agent such as KCl and phenylephrine. The ranking of agonist potency on 
the RFA was SC-46275 > sulprostone > 17-phenyl-PGE. KCl response on the RFA 
was also enhanced by pre-contraction with a threshold dose of sulprostone. The 
synergism was found to be mutual. Moreover, the vasoconstrictor effect evoked by 
these PGE analogues was found to be mediated by the EP3 receptor subtype, deduced 
from ranking of agonist potency and the experiments with SC-51322 and GR-32191 
which are EPi and TP receptor antagonists respectively. The ranking of agonist 
potency for the synergism was SC-46275 = sulprostone > 17-phenylephrine » 
fluprostenol (selective FP agonist). 
The synergistic action of EP3 receptor agonists and other vasoactive agents was 
found to be sensitive to nifedipine, a L-type Ca^ "^  channel blocker, indicating the 
- importance of Ca^ "^  influx. The contraction induced by phenylephrine/sulprostone 
combination was shown to be concentration-dependently inhibited by specific Rho-
kinase inhibitors, Y-27632 and H-1152. This report is the first of its kind that Rho-
kinase is involved in synergistic contractions produced by a weak and a strong 
vasoactive compounds. Since sulprostone and phenylephrine are selective agonists 
for their receptors (EP3 and ai respectively), the interaction is believed to be G 
protein-mediated. However, what mechanisms lie between the G protein and Rho-
kinase is not known. All the EP3 isoforms couple to Gi protein, which can be 
examined with pertussis toxin treatment. Involvement of Rho activation can be 
tested with Rho inhibitors such as C3 exoenzymes. The dependence on can 
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also be investigated to clarify the relationship between and Rho-kinase 
activation. 
Rho-kinase inhibitors have shown therapeutic potentials for example in hypertensive 
state (Uehata et al” 1997) and vasospasm (Shibuya et al., 1992). Therefore it is 
worthwhile to leam the role of Rho/Rho-kinase in the vasculature. The in vivo 
experiments with sulprostone in this study showed that in vitro findings cannot 
always translate to in vivo effect. It is interesting to find that sulprostone could 
induce vasodilatation in rat knee joint vascular bed. Further experiments are required 
to see if laser Doppler perfusion imaging is useful in studying the synergism between 
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